

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Peering into the &ldquo;rabbit hole&rdquo; of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/4-609/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/4-609" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract" />
    
            <meta name="og:title" content="F1000Research Article: Peering into the &ldquo;rabbit hole&rdquo; of publication bias and inadequate research transparency: Adding tangibility to the abstract.">
            <meta name="og:description" content="Read the latest article version by Martin Mayer, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="7887">
            <meta name="article-id" content="6878">
            <meta name="dc.title" content="Peering into the &ldquo;rabbit hole&rdquo; of publication bias and inadequate research transparency: Adding tangibility to the abstract">
            <meta name="dc.description" content="When patients seek medical care, they assume the treatment or advice they receive is based on a strong understanding of the human body and its processes. They also typically assume the care they receive is based on a strong understanding of the research literature pertaining to their well-being and any ailments for which they might seek care. However, publication bias and inadequate research transparency greatly threaten medical providers&rsquo; ability to practice evidence-based medicine in its truest form, and this in turn puts patients at unnecessary risk. The evidence of these issues existing is unequivocal. However, systematic reviews and other studies that present overviews of these issues &ndash; although certainly incredibly important in establishing the undeniable presence and pervasiveness of these issues &ndash; may inadvertently obfuscate the concreteness of these closely-related processes in action. Therefore, this article presents a &ldquo;case series&rdquo; of these detrimental issues in action in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear.">
            <meta name="dc.subject" content="Publication bias, research transparency, evidence-based medicine, antidepressants, gabapentin, celecoxib, rosiglitazone, oseltamivir">
            <meta name="dc.creator" content="Mayer, Martin">
            <meta name="dc.date" content="2015/11/05">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.6878.2">
            <meta name="dc.source" content="F1000Research 2015 4:609">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.relation" content="doi:10.12688/f1000research.6878.1">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Publication bias">
            <meta name="prism.keyword" content=" research transparency">
            <meta name="prism.keyword" content=" evidence-based medicine">
            <meta name="prism.keyword" content=" antidepressants">
            <meta name="prism.keyword" content=" gabapentin">
            <meta name="prism.keyword" content=" celecoxib">
            <meta name="prism.keyword" content=" rosiglitazone">
            <meta name="prism.keyword" content=" oseltamivir">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2015/11/05">
            <meta name="prism.volume" content="4">
            <meta name="prism.number" content="609">
            <meta name="prism.versionIdentifier" content="2">
            <meta name="prism.doi" content="10.12688/f1000research.6878.2">
            <meta name="prism.url" content="https://f1000research.com/articles/4-609">
            <meta name="citation_title" content="Peering into the &ldquo;rabbit hole&rdquo; of publication bias and inadequate research transparency: Adding tangibility to the abstract">
            <meta name="citation_abstract" content="When patients seek medical care, they assume the treatment or advice they receive is based on a strong understanding of the human body and its processes. They also typically assume the care they receive is based on a strong understanding of the research literature pertaining to their well-being and any ailments for which they might seek care. However, publication bias and inadequate research transparency greatly threaten medical providers&rsquo; ability to practice evidence-based medicine in its truest form, and this in turn puts patients at unnecessary risk. The evidence of these issues existing is unequivocal. However, systematic reviews and other studies that present overviews of these issues &ndash; although certainly incredibly important in establishing the undeniable presence and pervasiveness of these issues &ndash; may inadvertently obfuscate the concreteness of these closely-related processes in action. Therefore, this article presents a &ldquo;case series&rdquo; of these detrimental issues in action in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear.">
            <meta name="citation_description" content="When patients seek medical care, they assume the treatment or advice they receive is based on a strong understanding of the human body and its processes. They also typically assume the care they receive is based on a strong understanding of the research literature pertaining to their well-being and any ailments for which they might seek care. However, publication bias and inadequate research transparency greatly threaten medical providers&rsquo; ability to practice evidence-based medicine in its truest form, and this in turn puts patients at unnecessary risk. The evidence of these issues existing is unequivocal. However, systematic reviews and other studies that present overviews of these issues &ndash; although certainly incredibly important in establishing the undeniable presence and pervasiveness of these issues &ndash; may inadvertently obfuscate the concreteness of these closely-related processes in action. Therefore, this article presents a &ldquo;case series&rdquo; of these detrimental issues in action in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear.">
            <meta name="citation_keywords" content="Publication bias, research transparency, evidence-based medicine, antidepressants, gabapentin, celecoxib, rosiglitazone, oseltamivir">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Martin Mayer">
            <meta name="citation_author_institution" content="Department of Physician Assistant Studies, College of Allied Health Sciences, East Carolina University, Greenville, NC, 27858-4353, USA">
            <meta name="citation_publication_date" content="2015/11/05">
            <meta name="citation_volume" content="4">
            <meta name="citation_publication_number" content="609">
            <meta name="citation_version_number" content="2">
            <meta name="citation_doi" content="10.12688/f1000research.6878.2">
            <meta name="citation_firstpage" content="609">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/4-609/v2/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/4-609.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=7887 /> <input type=hidden id=articleId name=articleId value=6878 /> <input type=hidden id=xmlUrl value="/articles/4-609/v2/xml"/> <input type=hidden id=xmlFileName value="-4-609-v2.xml"> <input type=hidden id=article_uuid value=f17622e0-1667-4ef9-bcca-d9d7a18fc66b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.6878.2"/> <input type=hidden id=versionDoi value="10.12688/f1000research.6878.2"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/4-609"
  },
  "headline": "Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding...",
  "datePublished": "2015-08-21T16:24:31",
  "dateModified": "2015-11-05T12:17:05",
  "author": [
    {
      "@type": "Person",
      "name": "Martin Mayer"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "When patients seek medical care, they assume the treatment or advice they receive is based on a strong understanding of the human body and its processes. They also typically assume the care they receive is based on a strong understanding of the research literature pertaining to their well-being and any ailments for which they might seek care. However, publication bias and inadequate research transparency greatly threaten medical providers&rsquo; ability to practice evidence-based medicine in its truest form, and this in turn puts patients at unnecessary risk. The evidence of these issues existing is unequivocal. However, systematic reviews and other studies that present overviews of these issues &ndash; although certainly incredibly important in establishing the undeniable presence and pervasiveness of these issues &ndash; may inadvertently obfuscate the concreteness of these closely-related processes in action. Therefore, this article presents a &ldquo;case series&rdquo; of these detrimental issues in action in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/4-609/v2",
            "name": "Peering into the “rabbit hole” of publication bias and inadequate..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Peering into the “rabbit hole” of publication bias and inadequate... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=7887 data-id=6878 data-downloads="" data-views="" data-scholar="10.12688/f1000research.6878.2" data-recommended="" data-doi="10.12688/f1000research.6878.2" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/4-609/v2/pdf?article_uuid=f17622e0-1667-4ef9-bcca-d9d7a18fc66b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-6878-2> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-6878-2 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-6878-2 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Mayer M. Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract [version 2; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2015, <b>4</b>:609 (<a class=new-orange href="https://doi.org/10.12688/f1000research.6878.2" target=_blank>https://doi.org/10.12688/f1000research.6878.2</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-6878-2" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=6878 id=track-article-signin-6878 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/6878?target=/articles/4-609/v2">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=7887 /> <input name=articleId type=hidden value=6878 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Opinion Article </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <span title="A revision, usually following reviewer/reader feedback" class=" updated-box updated-box-bg orange-bg revised helper">Revised</span> <h1>Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract</h1><span class=other-info> [version 2; peer review: awaiting peer review]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:mayerm@ecu.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Martin Mayer</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:mayerm@ecu.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Martin Mayer</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 05 Nov 2015 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.6878.2"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Physician Assistant Studies, College of Allied Health Sciences, East Carolina University, Greenville, NC, 27858-4353, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <em>AWAITING PEER REVIEW</em> </span> </div> </div> </div> <div class="f1r-article-desk padding-top"> <div class=article-collection-wrapper> <div class="o-media o-media--sm o-media--center"> <div class=o-media__img> <a href="https://f1000research.com/collections/all-trials-matter" title="Open Collection"><img src="https://f1000researchdata.s3.amazonaws.com/thumbnails/887d4a2e-0aff-4424-bf7f-bb76290ac862_collection.thumbnail"></a> </div> <div class=o-media__body> <p class="u-mt--0 u-mb--0">This article is included in the <a href="https://f1000research.com/collections/all-trials-matter">All trials matter</a> collection.</p> </div> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> When patients seek medical care, they assume the treatment or advice they receive is based on a strong understanding of the human body and its processes. They also typically assume the care they receive is based on a strong understanding of the research literature pertaining to their well-being and any ailments for which they might seek care. However, publication bias and inadequate research transparency greatly threaten medical providers’ ability to practice evidence-based medicine in its truest form, and this in turn puts patients at unnecessary risk. The evidence of these issues existing is unequivocal. However, systematic reviews and other studies that present overviews of these issues – although certainly incredibly important in establishing the undeniable presence and pervasiveness of these issues – may inadvertently obfuscate the concreteness of these closely-related processes in action. Therefore, this article presents a “case series” of these detrimental issues in action in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Publication bias, research transparency, evidence-based medicine, antidepressants, gabapentin, celecoxib, rosiglitazone, oseltamivir </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Martin Mayer (<a href="mailto:mayerm@ecu.edu">mayerm@ecu.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Martin Mayer </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Truly none, but in the interest of full disclosure, I am a current member of the U.S. Board of <i>BMJ</i> Fellows. I do not receive any compensation from <i>The BMJ</i> or anyone else as a result of this. I disclose this here since this article cites works published in <i>The BMJ</i> and ultimately draws attention to their efforts in combating issues with publication bias and inadequate research transparency. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2015 Mayer M. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Mayer M. Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract [version 2; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2015, <b>4</b>:609 (<a href="https://doi.org/10.12688/f1000research.6878.2" target=_blank>https://doi.org/10.12688/f1000research.6878.2</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 21 Aug 2015, <b>4</b>:609 (<a href="https://doi.org/10.12688/f1000research.6878.1" target=_blank>https://doi.org/10.12688/f1000research.6878.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 05 Nov 2015, <b>4</b>:609 (<a href="https://doi.org/10.12688/f1000research.6878.2" target=_blank>https://doi.org/10.12688/f1000research.6878.2</a>)</span> </div> <div class="update-box-wrapper update-text-view-control article-updated-box "> <h2 class="h2-title no-top-margin"> <span title="A revision, usually following reviewer/reader feedback" class=" updated-box updated-box-bg orange-bg revised ">Revised</span> Amendments from Version 1 <span class="research-layout f1r-article-mobile-inline update-box-control"> <span class="f1r-icon icon-14_more_small big midgrey"></span> <span class="f1r-icon icon-10_less_small big midgrey" style="display: none;"></span> </span> </h2> <div class=f1r-article-desk> <p>In this revised version, I very slightly changed diction in one area of the&nbsp;antidysrhythmic and celecoxib sections to improve readability. I also provided much additional detail on the oseltamivir meta-analyses for interested readers. Importantly, these revisions merely serve to augment the original version, not to change any messages or statements concerning the evidence.</p> </div> <div class="f1r-article-mobile research-layout article-page-general-text-mobile padding-top-20" style="display: none;"> In this revised version, I very slightly changed diction in one area of the&nbsp;antidysrhythmic and celecoxib sections to improve readability. I also provided much additional detail on the oseltamivir meta-analyses for interested readers. Importantly, these revisions merely serve to augment the original version, not to change any messages or statements concerning the evidence. </div> <p class=f1r-article-desk> </p> <span class=f1r-article-mobile> <div class="margin-top-30 margin-bottom research-layout is-centered" style="display: none;"> <a href="#article-reports"> <button class="primary orange extra-padding">READ REVIEWER RESPONSES</button> </a> </div> </span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e149>Introduction</h2><p class="" id=d34243e152>Recent systematic reviews and meta-analyses from 2009, 2010, and 2013 all confirm the widespread presence of publication bias in the medical literature, with the two most recent studies finding around 50% or more of studies go unpublished.<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup> The failure to publish studies is often due to the studies having so-called “negative” or non-significant findings.<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup> In a similar manner, issues with inadequate research transparency continue to loom large, with important elements of a study changing from the original protocol to the final manuscript that appears in the peer-reviewed literature without proper acknowledgement of such changes in the final manuscript.<sup><a href="#ref-1">1</a>,<a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup> The existence and persistence of these two closely-related issues carry profoundly detrimental implications for the evidence base from which researchers and medical providers operate. Importantly, these issues put patients at risk of receiving incomplete or inaccurate medical advice and/or an intervention that appears much more effective or advantageous than it really is, is less than ideal for the condition or situation in question, or is actually harmful. Such a claim should not be taken lightly. The systematic reviews and other studies aforementioned<sup><a href="#ref-1">1</a>–<a href="#ref-6">6</a></sup> collectively provide important and robust evidence of the incontrovertible existence and pervasiveness of these issues; however, these studies, although incredibly valuable, might still blur somewhat the concreteness of these issues. Therefore, it is instructive, and perhaps even crucial, to go deeper into the “rabbit hole,” where one finds many well-documented specific examples that add unequivocal tangibility to the dire importance and relevance of these issues. To this end, this article presents a “case series” that demonstrates the very real effects publication bias and inadequate research transparency have on the medical literature, and in turn, the very real effects these issues can have on patient care and the practice and furthering of evidence-based medicine.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e189>Heartbreak, depression, and pain</h2><div class=section><a name=d34243e192 class=n-a></a><h3 class=section-title>It breaks my heart to tell you…</h3><p class="" id=d34243e197>After suffering a myocardial infarction (MI), some people develop dysrhythmias or aberrant heartbeats. Sometimes this is transient, but in other cases this can portend an increased risk for potentially lethal complications. Indeed, those who do develop persistent dysrhythmias have a higher risk of death than those who do not. Given this common medical knowledge, the historical question was: Should medical providers proactively administer medications (specifically, class I antidysrhythmic agents) that act to suppress dysrhythmias after a patient has suffered a MI (post-MI antidysrhythmic prophylaxis)?</p><p class="" id=d34243e200>This is precisely what used to be done, but when Furberg completed his 1983 review assessing the impacts of this practice, there was no evidence of benefit from doing this (there was not even a trend suggesting possible benefit); in fact, Furberg even mentioned some emerging evidence that these agents might be harmful in this setting.<sup><a href="#ref-7">7</a></sup> However, he still concluded that the finding of no benefit seemed the least likely possibility, and instead, he concluded the most likely explanation was that the class I antidysrhythmics did offer mortality benefit that was probably obscured by methodological shortcomings of the available trials.<sup><a href="#ref-7">7</a></sup> These agents continued to be used for almost an entire decade after his review. Then, the trials CAST and CAST-II were published in 1991 and 1992, followed by a meta-analysis in 1993.<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup> All these studies found that post-MI antidysrhythmic prophylaxis not only offered no benefit, but also caused substantial harm in the form of excess death.<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup></p><p class="" id=d34243e224>The harm amounted to the deaths of tens of thousands of people in the 1980s for every year they were used (especially later in the 1980s), with a contextual comparison of the <i>annual</i> number of deaths caused during the peak of their use quite possibly being greater than the number of U.S. military personnel killed in the <i>entirety</i> of the Vietnam War. The upper-level estimate is approximately 65,000 – 70,000 excess deaths per year, and even the most conservative estimate still yields approximately 28,000 excess deaths per year of use. The total excess death estimate is in the hundreds of thousands.<sup><a href="#ref-11">11</a></sup></p><p class="" id=d34243e236>The story gets worse. In 1993, Cowley and colleagues published an article describing a randomized, double-blind, placebo-controlled trial conducted in 1980, prior to the publication of Furberg’s 1983 review.<sup><a href="#ref-12">12</a></sup> In this study, there were nine deaths in the antidysrhythmic (lorcainide) group of 48 patients (18.75%; the abstract mistakenly indicates there were 49 patients in the lorcainide group, but there were actually 48), and only one death in the placebo group of 47 patients (2.13%).</p><p class="" id=d34243e244>Although the authors never conducted any statistical analysis on the mortality data, if one were to consider further the mortality event rates (in what is obviously a <i>post hoc</i> analysis), one would find an absolute increase in risk of death of 16.62% over the six-week period of the study for those in the lorcainide group (95% confidence interval [CI], 4.21% – 29.93%), and by Fisher’s exact test, the difference between the two groups would have a P value of 0.015 (rounded to three decimal places). Based on these results, one additional and unnecessary death was caused for about every six patients treated for six weeks with lorcainide for post-MI antidysrhythmic prophylaxis.</p><p class="" id=d34243e250>Since the development of lorcainide was “abandoned for commercial reasons,” the study was not initially published.<sup><a href="#ref-12">12(p166)</a></sup> Though the authors maintain they initially thought the higher incidence of death in the lorcainide group was due to chance, the authors later came to rightly regard this as an “example of publication bias,” and they also recognized that, had the study been properly published, it “might have provided an early warning of trouble ahead.”<sup><a href="#ref-12">12(p166)</a></sup></p></div><div class=section><a name=d34243e261 class=n-a></a><h3 class=section-title>Depressing, right?</h3><p class="" id=d34243e266>In 2008, Turner and colleagues published a striking review of 12 antidepressants where they compared all the phase II and phase III trials submitted to the FDA to the corresponding trials available in the peer-reviewed literature.<sup><a href="#ref-13">13</a></sup> The 12 antidepressants included selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, paroxetine CR, sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs; venlafaxine, venlafaxine XR, duloxetine), and agents with other mechanisms of action (bupropion SR, mirtazapine, nefazodone). <a href="#f1">Figure 1</a> shows the primary results graphically, along with several additional graphical representations of the study’s data. How is this possible? Of the 38 positive studies, all but one were published, yielding 37 positive studies in the peer-reviewed literature. Of the 36 not-positive (24 negative and 12 questionable) studies, three were correctly published as negative, 22 were not published at all, and 11 were published in such a way as to make the results seem positive (a manner of reporting referred to as “spinning”).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure1.gif"><img alt="b0794328-9657-49d0-a52d-73caf908a0f9_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure1.gif"></a><div class=caption><h3>Figure 1. Graphical representations of studies and study data concerning antidepressants as submitted to the FDA versus studies and study data appearing in the peer-reviewed literature.</h3><p id=d34243e286>All graphs were created using data from Turner and colleagues’ 2008 publication. Percentages are rounded to nearest tenth of a percentage point.<sup><a href="#ref-13">13</a></sup></p></div></div><p class="" id=d34243e296>Interestingly, Melander and colleagues published similarly disconcerting findings in 2003 when they found troubling issues with the SSRI literature compared to the data available at the Swedish drug regulatory authority.<sup><a href="#ref-14">14</a></sup> Out of 42 studies submitted to the drug regulatory authority, 21 showed a significant effect for the primary outcome (SEPO) and 21 found no significant effect for the primary outcome (NSEPO). However, in the peer-reviewed literature, there were 22 corresponding stand-alone publications finding SEPO; interestingly, three of the 21 studies finding SEPO were published as a stand-alone publication twice, with two of the 21 studies finding SEPO never appearing as a stand-alone publication (their data were pooled with other studies for a pooled-results publication). On the other hand, of the 21 studies finding NSEPO, only six were published as a stand-alone publication, the data from four never appeared in any fashion in the peer-reviewed literature, and the remaining 11 only had their data presented in a pooled-results publication incorporating data from other studies. All but one of the pooled-results publications had an amalgamation of studies finding SEPO and NSEPO, with one pooled-results publication being comprised of only two studies finding NSEPO. Additionally, the pooled publications were not always forthright about pooling. For instance, two of the pooled publications for one drug were reported as a “double-blind comparison” and “a large multicentre [sic] study.”<sup><a href="#ref-14">14(p2)</a></sup> If this were not already enough, Melander and colleagues also noted that only two of the stand-alone publications presented both an intention-to-treat (ITT) and per-protocol (PP) analysis. The remaining publications presented only one analysis, which tended to be the typically-more-treatment-favorable PP analysis (only 24% of the stand-alone publications reported an ITT analysis). Melander and colleagues rightly conclude: <div class=list><a name=d34243e306 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e312><span class=label></span> “<i>[F]or anyone who relies on published data alone to choose a specific drug, our results should be a cause for concern. Without access to all studies (positive as well as negative, published as well as unpublished) and without access to alternative analyses (intention to treat as well as per protocol), any attempt to recommend a specific drug is likely to be based on biased evidence</i>.”<sup><a href="#ref-14">14(p4)</a></sup></p></li></ul></div> </p></div><div class=section><a name=d34243e325 class=n-a></a><h3 class=section-title>Well, that hurts</h3><p class="" id=d34243e330>Various aspects of the mishandlings of studies for off-label uses of gabapentin are well-documented in <i>NEJM, Trials, and PLoS Medicine</i>.<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup> These studies primarily surrounded treatment of painful conditions (migraine prophylaxis and neuropathic and nociceptive pain), but a smaller portion of the studies investigated use of gabapentin as an adjunctive agent in bipolar disorder. Mishandlings of the data essentially all revolve around not publishing data from studies in a forthright and transparent manner, with infractions such as delaying publication of negative results, never publishing negative results as a full research article, or altering study protocols (particularly study outcomes) without adequate transparency when doing so.<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup> For instance, primary outcomes specified in protocols were sometimes not reported in the corresponding publication or were reported as secondary outcomes; likewise, primary outcomes that did not appear anywhere in the original protocol were added to publications. Proper disclosure of such changes in the primary outcome was variable (even though it should have been universal when it occurred). Additional concerning findings included discrepancies in the results of statistical analyses between internal research reports and journal publications, and there were even discrepancies in the analytic methods used, such as varying definitions of ITT analysis, with one article even noting “In no case did the documents describe an ITT analysis according to the widely accepted definition [of analyzing] all randomized participants in the groups to which they were assigned.”<sup><a href="#ref-17">17(p10)</a></sup> Internal company documents provided in the <i>Trials</i> publication and associated additional file are also distressing (<a href="#f2">Figure 2</a>).<sup><a href="#ref-16">16</a></sup> These documents add an unequivocal degree of tangibility to the issues of publication bias and inadequate research transparency, and it is worth noting these documents and others that contributed to these three publications became available to the public as a result of litigation over fraudulent sales practices in its marketing of Neurontin<sup>®</sup> (gabapentin).<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup></p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure2.gif"><img alt="b0794328-9657-49d0-a52d-73caf908a0f9_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure2.gif"></a><div class=caption><h3>Figure 2. A sampling of internal company memos and emails concerning gabapentin (Neurontin<sup>®</sup>) that became available to the public as a result of litigation over fraudulent sales practices in the marketing of gabapentin.</h3><p id=d34243e387>These and other documents are provided in the open-access <i>Trials</i> article and the associated additional file. Page numbers provided with the images shown here are for the supplemental file.<sup><a href="#ref-16">16</a></sup></p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e404>Criticism and concern over celecoxib</h2><div class=section><a name=d34243e407 class=n-a></a><h3 class=section-title>Adding insult to injury…</h3><p class="" id=d34243e412>The randomized, double-blind CLASS trial purportedly established the gastrointestinal safety advantage of celecoxib (Celebrex<sup>®</sup>), a cyclooxygenase-2 (COX-2) selective, non-steroidal, anti-inflammatory drug (NSAID), over other nonselective NSAIDs.<sup><a href="#ref-18">18</a></sup> While initially widely heralded, discussed, and disseminated, there are considerable issues with the CLASS trial: the <i>JAMA</i> publication of the CLASS trial reports six-month data for a single trial, but in reality, there were two trials that were pooled together, and the trials ran for 65 weeks and 52 weeks, respectively.<sup><a href="#ref-18">18</a>–<a href="#ref-25">25</a></sup> The stark difference is odd and should immediately give one pause and a desire to clarify the differences. Indeed, upon reviewing the FDA literature, one finds there were originally two protocols: N49-98-02-035 (dated January 26, 1998) and N49-98-02-102 (dated August 24, 1998).<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup> Following a total of eight protocol amendments (all of which took place with blinding preserved), the protocol pre-specified the trials were to run for the aforementioned durations of follow-up or until a pre-specified number of events had occurred (20 in each trial or 45 between the two trials).<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup> The protocol also pre-specified a plan to pool the data for the patients receiving celecoxib.<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup> The events accrued at rates lower than predicted, which affected the duration for which the trials ran; indeed, one of the amendments was to lengthen the study period of one of the trials by three months in order to reach the target number of events.<sup><a href="#ref-21">21</a></sup></p><p class="" id=d34243e457>The story does not end there, though: When all the data were analyzed according to the pre-specified protocol instead of how the authors reported the six-month data in <i>JAMA</i>, the rate of clinically-significant upper gastrointestinal events (CSUGIEs) in celecoxib recipients versus those who received a comparator nonselective NSAID (ibuprofen or diclofenac) was not statistically significantly different.<sup><a href="#ref-19">19</a>–<a href="#ref-25">25</a></sup> The authors’ attempt to reply to reader criticism failed to substantiate their presentation of the truncated data, which they should have known would be the case since the FDA reviewers also pointed out why analysis of the data as it is presented in <i>JAMA</i> is inappropriate.<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a>,<a href="#ref-22">22</a>–<a href="#ref-25">25</a></sup> For example, in the review he prepared for the FDA, Goldkind stated plainly that the <i>post hoc</i> decision to report six-month data instead of all the relevant data was “not statistically valid or supportable,” and he therefore decided “[b]ased on the lack of adequate rationale, these <i>post hoc</i> analyses will not be further discussed or presented in this review.”<sup><a href="#ref-20">20(p51)</a></sup> Lu similarly called the decision to report the truncated six-month data “not valid.”<sup><a href="#ref-19">19(p8)</a></sup></p><p class="" id=d34243e500>Furthermore, the FDA literature shows that the original primary outcome event was defined as CSUGIEs, which was further defined as perforation, upper gastrointestinal bleeding, or gastric outlet obstruction.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup> However, celecoxib failed to show significant benefit for CSUGIEs even in the methodologically-invalid, <i>post hoc</i>, six-month truncation analysis.<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup> <a href="#T1">Table 1</a> below provides the CSUGIE incidence rate data from the FDA literature for the entire study period and for the untenable six-month truncation point. Only by combining CSUGIEs with symptomatic gastroduodenal ulcers that did not cause a CSUGIE (GDUs) did celecoxib demonstrate a statistically significant benefit versus the pooled NSAIDs group, and the addition of GDUs to the original primary outcome of CSUGIEs was another <i>post hoc</i> decision not transparently addressed in the <i>JAMA</i> publication.<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup> Nevertheless, the inappropriately truncated six-month data for this <i>post hoc</i> altered primary outcome are saluted by the authors in their publication.<sup><a href="#ref-18">18</a></sup> <a href="#T2">Table 2</a> below provides the incidence rate data from the FDA literature for the <i>post hoc</i> altered primary outcome of CSUGIEs plus GDUs. It is also important to note that GDUs are a clinically weaker and logistically more problematic outcome to use as part of a primary outcome measure compared to the relatively much more robust composite outcome of CSUGIEs. Goldkind gives a succinct and telling overview of the problems inherent in including GDUs as a part of the primary outcome measure on page 22 of his review for the FDA.<sup><a href="#ref-20">20</a></sup></p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Crude incidence rates for clinically-significant upper gastrointestinal event (CSUGIE) seen in the FDA documentation for pooled data from N49-98-02-035 and N49-98-02-102.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup></h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34243e571 class=n-a></a><thead><a name=d34243e573 class=n-a></a><tr><a name=d34243e575 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e577 class=n-a></a></th><th align=center colspan=1 rowspan=2><a name=d34243e579 class=n-a></a>Celecoxib<br class=br>400 mg BID<br class=br>n = 3,987</th><th align=center colspan=1 rowspan=2><a name=d34243e586 class=n-a></a>Diclofenac<br class=br>75 mg BID<br class=br>n = 1,996</th><th align=center colspan=1 rowspan=2><a name=d34243e593 class=n-a></a>Ibuprofen<br class=br>800 mg TID<br class=br>n = 1,985</th><th align=center colspan=3 rowspan=1><a name=d34243e600 class=n-a></a>Log-rank P values for celecoxib<br class=br>vs.</th></tr><tr><a name=d34243e606 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e608 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d34243e610 class=n-a></a>diclofenac</th><th align=center colspan=1 rowspan=1><a name=d34243e613 class=n-a></a>ibuprofen</th><th align=center colspan=1 rowspan=1><a name=d34243e616 class=n-a></a>both</th></tr></thead><tbody><a name=d34243e621 class=n-a></a><tr><a name=d34243e623 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e625 class=n-a></a>26-week CR</td><td align=center colspan=1 rowspan=1><a name=d34243e628 class=n-a></a>0.28%</td><td align=center colspan=1 rowspan=1><a name=d34243e631 class=n-a></a>0.45%</td><td align=center colspan=1 rowspan=1><a name=d34243e634 class=n-a></a>0.55%</td><td align=center colspan=1 rowspan=1><a name=d34243e637 class=n-a></a>0.264</td><td align=center colspan=1 rowspan=1><a name=d34243e641 class=n-a></a>0.073</td><td align=center colspan=1 rowspan=1><a name=d34243e644 class=n-a></a>0.092</td></tr><tr><a name=d34243e648 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e650 class=n-a></a># per 100 pt-yrs</td><td align=center colspan=1 rowspan=1><a name=d34243e653 class=n-a></a>0.76</td><td align=center colspan=1 rowspan=1><a name=d34243e656 class=n-a></a>1.27</td><td align=center colspan=1 rowspan=1><a name=d34243e659 class=n-a></a>1.63</td><td colspan=1 rowspan=1><a name=d34243e662 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e665 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e667 class=n-a></a></td></tr><tr><a name=d34243e670 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e672 class=n-a></a>52-week CR</td><td align=center colspan=1 rowspan=1><a name=d34243e675 class=n-a></a>0.43%</td><td align=center colspan=1 rowspan=1><a name=d34243e678 class=n-a></a>0.50%</td><td align=center colspan=1 rowspan=1><a name=d34243e681 class=n-a></a>0.55%</td><td align=center colspan=1 rowspan=1><a name=d34243e684 class=n-a></a>0.640</td><td align=center colspan=1 rowspan=1><a name=d34243e688 class=n-a></a>0.414</td><td align=center colspan=1 rowspan=1><a name=d34243e691 class=n-a></a>0.450</td></tr><tr><a name=d34243e695 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e697 class=n-a></a># per 100 pt-yrs</td><td align=center colspan=1 rowspan=1><a name=d34243e700 class=n-a></a>0.73</td><td align=center colspan=1 rowspan=1><a name=d34243e703 class=n-a></a>0.93</td><td align=center colspan=1 rowspan=1><a name=d34243e706 class=n-a></a>0.98</td><td colspan=1 rowspan=1><a name=d34243e709 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e712 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e714 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34243e721 class=n-a></a><p id=d34243e723> Table recreated from data tables in FDA documentation.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup></p><p id=d34243e732>BID indicates twice a day; CR, crude rate; pt-yrs, patient-years; TID, three times a day.</p></div></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Crude incidence rates for clinically-significant upper gastrointestinal event (CSUGIE) plus symptomatic gastroduodenal ulcer not resulting in a CSUGIE (GDU) seen in the FDA documentation for the pooled data from N49-98-02-035 and N49-98-02-102.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup></h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34243e756 class=n-a></a><thead><a name=d34243e758 class=n-a></a><tr><a name=d34243e760 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e762 class=n-a></a></th><th align=center colspan=1 rowspan=2><a name=d34243e764 class=n-a></a>Celecoxib<br class=br>400 mg BID<br class=br>n = 3,987</th><th align=center colspan=1 rowspan=2><a name=d34243e771 class=n-a></a>Diclofenac<br class=br>75 mg BID<br class=br>n = 1,996</th><th align=center colspan=1 rowspan=2><a name=d34243e778 class=n-a></a>Ibuprofen<br class=br>800 mg TID<br class=br>n = 1,985</th><th align=center colspan=3 rowspan=1><a name=d34243e785 class=n-a></a>Log-rank P values for celecoxib<br class=br>vs.</th></tr><tr><a name=d34243e791 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e793 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d34243e795 class=n-a></a>diclofenac</th><th align=center colspan=1 rowspan=1><a name=d34243e798 class=n-a></a>ibuprofen</th><th align=center colspan=1 rowspan=1><a name=d34243e801 class=n-a></a>both</th></tr></thead><tbody><a name=d34243e806 class=n-a></a><tr><a name=d34243e808 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e810 class=n-a></a>26-week CR</td><td align=center colspan=1 rowspan=1><a name=d34243e813 class=n-a></a>0.75%</td><td align=center colspan=1 rowspan=1><a name=d34243e816 class=n-a></a>1.00%</td><td align=center colspan=1 rowspan=1><a name=d34243e819 class=n-a></a>1.46%</td><td align=center colspan=1 rowspan=1><a name=d34243e822 class=n-a></a>0.308</td><td align=center colspan=1 rowspan=1><a name=d34243e826 class=n-a></a>0.005</td><td align=center colspan=1 rowspan=1><a name=d34243e829 class=n-a></a>0.023</td></tr><tr><a name=d34243e833 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e835 class=n-a></a># per 100 pt-yrs</td><td align=center colspan=1 rowspan=1><a name=d34243e838 class=n-a></a>2.08</td><td align=center colspan=1 rowspan=1><a name=d34243e841 class=n-a></a>2.82</td><td align=center colspan=1 rowspan=1><a name=d34243e844 class=n-a></a>4.31</td><td colspan=1 rowspan=1><a name=d34243e847 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e850 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e852 class=n-a></a></td></tr><tr><a name=d34243e855 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e857 class=n-a></a>52-week CR</td><td align=center colspan=1 rowspan=1><a name=d34243e860 class=n-a></a>1.05%</td><td align=center colspan=1 rowspan=1><a name=d34243e863 class=n-a></a>1.30%</td><td align=center colspan=1 rowspan=1><a name=d34243e866 class=n-a></a>1.76%</td><td align=center colspan=1 rowspan=1><a name=d34243e869 class=n-a></a>0.296</td><td align=center colspan=1 rowspan=1><a name=d34243e873 class=n-a></a>0.017</td><td align=center colspan=1 rowspan=1><a name=d34243e876 class=n-a></a>0.040</td></tr><tr><a name=d34243e880 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d34243e882 class=n-a></a># per 100 pt-yrs</td><td align=center colspan=1 rowspan=1><a name=d34243e885 class=n-a></a>1.85</td><td align=center colspan=1 rowspan=1><a name=d34243e888 class=n-a></a>2.41</td><td align=center colspan=1 rowspan=1><a name=d34243e891 class=n-a></a>3.21</td><td colspan=1 rowspan=1><a name=d34243e894 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e897 class=n-a></a></td><td colspan=1 rowspan=1><a name=d34243e899 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34243e906 class=n-a></a><p id=d34243e908> Table recreated from data tables in FDA documentation.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup></p><p id=d34243e917>BID indicates twice a day; CR, crude rate; pt-yrs, patient-years; TID, three times a day.</p></div></div></div><p class="" id=d34243e923>Also of interest is FDA documentation indicating that the sponsor specified original intent to compare the event rate in the group receiving celecoxib (n = 3,987) to <i>each</i> of the groups receiving diclofenac (n = 1,996) and ibuprofen (n = 1,985) separately as long as the outcome data for the pooled celecoxib group were significantly different from the pooled NSAID group (this stepwise approach was employed to prevent type I error).<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup> However, if one reads the <i>JAMA</i> article, one only finds data for the celecoxib group versus the pooled NSAID group, even though the authors noted a significant difference for the celecoxib group versus the pooled NSAID group for the <i>post hoc</i> altered primary outcome.<sup><a href="#ref-18">18</a></sup> This too is peculiar, and it is troubling to note that in the data available in the FDA documents, celecoxib repeatedly failed to separate significantly from diclofenac.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup> Indeed, celecoxib was not significantly different from diclofenac regardless of whether one assessed CSUGIEs or CSUGIEs plus GDUs, this remained the case for both outcomes when considering the untenable six-month analysis and the analysis over the entire period of data collection, and it still remained the case in additional subgroup analyses (that were not pre-specified) that considered only those who did not take aspirin.<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup> (The aspirin subgroup analysis is rightly questioned by Lu, who noted “at least 34” subgroup analyses were conducted in an exploratory manner “with no pre-specified plan of statistical inference,” and the lack of <i>a priori</i> specification of subgroup analyses based on aspirin is made even more problematic given the failure to show statistical significance in the original primary endpoint.<sup><a href="#ref-19">19(p9)</a></sup>) The failure of celecoxib to demonstrate significant benefit compared to diclofenac in the aforementioned analyses should again give one pause. Indeed, as Witter noted in his review for the FDA: “Therefore, particularly for making drug class (i.e. COX-2 vs. NSAIDs) comparisons, it could be argued that beating one NSAID does not mean you beat them all, but losing to one NSAID (or failing to beat it) is losing to them all.”<sup><a href="#ref-21">21(p76)</a></sup></p><p class="" id=d34243e971>There is still more to the story. As shown below (<a href="#f3">Figure 3</a>), internal company documents suggest additional troubling behavior.<sup><a href="#ref-26">26</a>–<a href="#ref-28">28</a></sup> However, some of the documents also show that some expressed concern that presentation of the truncated six-month data amounted to “cherry picking” (Mona Wahba)<sup><a href="#ref-26">26(p8115)</a></sup> or “data massage … for no other reason that [sic] it happens to look better” (Emilio Arbe).<sup><a href="#ref-26">26(p8112)</a></sup> Arbe also indicated he “wouldn’t feel too comfortable presenting a fudged version of the facts.”<sup><a href="#ref-26">26(p8113)</a></sup></p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure3.gif"><img alt="b0794328-9657-49d0-a52d-73caf908a0f9_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure3.gif"></a><div class=caption><h3>Figure 3. Sampling of internal company documents that are now a matter of public record after being unsealed by a federal judge as part of a securities fraud case against the parent company of celecoxib.</h3><p id=d34243e1005>The items above show content regarding strategic planning on what would be done with the celecoxib data based on the favorability of the results and a research director’s response after learning that a symposium offered during a medical conference claimed the CLASS trial demonstrated celecoxib’s superior gastrointestinal safety profile compared to nonselective NSAIDs.<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup></p></div></div><p class="" id=d34243e1018>In the trial data discussed above, the dosing regimen of the medications was as follows: celecoxib, 400 mg twice a day; diclofenac, 75 mg twice a day; and ibuprofen, 800 mg three times a day. While the doses of diclofenac and ibuprofen are at the higher end of officially-recommended doses for treatment of pain caused by osteoarthritis and rheumatoid arthritis, the dose of celecoxib used in the trials was two to four times higher than the doses officially recommended for the same indications, respectively. FDA documents indicate the celecoxib dose was deliberately chosen to “ensure that the ulcerogenic potential of celecoxib was rigorously assessed.”<sup><a href="#ref-21">21(p10)</a></sup> Unfortunately, instead of providing a rigorous and reassuring assessment, comparing the FDA literature and internal company documents to the official CLASS publication leaves one with little more than profound disillusionment and considerable uncertainty.</p><p class="" id=d34243e1025>Might doses such as 100–200 mg twice daily – the doses typically used in clinical practice – fare differently for similar outcomes? Unfortunately, there is no reliable answer to this question. Some might cite SUCCESS-I, CONDOR, and GI-REASONS (the other major trials of celecoxib versus nonselective NSAIDs) as providing the answers, but doing so is mistaken. For example, the SUCCESS-I trial was a randomized, double-blind trial studying celecoxib at two doses – 100 mg twice daily (n = 4,393) and 200 mg twice daily (n = 4,407) – versus the nonselective NSAIDs naproxen at 500 mg twice daily (n = 905) and diclofenac at 50 mg twice daily (n = 3,489); however, amidst limitations to the study, perhaps most notably for the discussion at hand is the fact that exposure to the medications only lasted 12 weeks, thus precluding any conclusion about long-term effects.<sup><a href="#ref-29">29</a></sup> CONDOR was a randomized, double-blind trial that studied celecoxib 200 mg twice daily (n = 2,238) versus diclofenac slow release 75 mg twice daily plus omeprazole 20 mg once a day (n = 2,246).<sup><a href="#ref-30">30</a></sup> The CONDOR trial ran for six months, which, although better than 12 weeks, is still a disappointing and questionable duration given the aforementioned discussion of the CLASS trial data. This trial has other limitations, but again foregoing such considerations for the discussion at hand, it is still instructive to appraise the actual event rates and the components of the primary composite outcome for the six-month duration of the trial. Notably, the rates of gastroduodenal hemorrhage; gastric outlet obstruction; gastroduodenal, small-bowel, or large-bowel perforation; small-bowel hemorrhage; and large-bowel hemorrhage were <i>identical</i> between the two groups. As shown in <a href="#T3">Table 3</a> below, the statistically significant difference reported for the primary composite outcome was driven predominantly by the study-defined outcome of clinically-significant anemia of presumed occult gastrointestinal origin, including possible small-bowel blood loss, with a smaller contribution from clinically-significant anemia judged to be from a visualized gastrointestinal lesion. Similar findings are seen in the GI-REASONS trial, although it had a smaller difference in the primary composite outcome.<sup><a href="#ref-31">31</a></sup> GI-REASONS was another randomized trial that ran for six months, but it was open-label with blinded endpoint assessment and assessed celecoxib (n = 4,035) versus freely-chosen nonselective NSAIDs (n = 4,032). It too has other limitations, but setting those issues aside again to consider the six-month event rates, we again see a statistically significant difference reported for the primary composite outcome (the composition of which was very similar, but not identical, to the primary composite outcome seen in the CONDOR trial). However, as seen in <a href="#T4">Table 4</a> below, the difference in the primary composite outcome was again mostly due to differences in clinically-significant anemia of presumed occult gastrointestinal origin, including possible small bowel blood loss, and in this trial, the difference in clinically-significant anemia judged to be from a visualized gastrointestinal lesion was notably smaller, differing by only two events between the groups. Although CONDOR and GI-REASONS had similar durations and outcomes (thereby perhaps tempting some to compare the event rates for the primary composite outcomes to one another), one must note there were differences in methodology (e.g. double-blind in CONDOR versus open-label with blinded outcome assessment in GI-REASONS, fixed-dose and fixed-drug comparison in CONDOR versus clinician-determined dosing and allowance for use of and switching between different nonselective NSAIDs in the nonselective NSAID group in GI-REASONS) and patient population (e.g. exclusion of patients who tested positive for <i>Helicobacter pylori</i> in CONDOR versus allowance of such patients in GI-REASONS). Still, perhaps the most salient and troubling feature is that no trial has ever continued long enough to resolve lingering uncertainties raised by the full dataset behind the CLASS trial regarding the long-term assessment of celecoxib compared to nonselective NSAIDs, and simply meta-analyzing the available trials cannot resolve this uncertainty, either. Finally, all of these trials had significant conflict of interest with respect to trial funding from the parent company for celecoxib and/or financial relationships with the parent company for celecoxib, up to and including working exclusively for the parent company. Although this is not necessarily an incorrigible flaw by default, one is prudent to be cognizant of such conflicts of interest, and given the mishandlings of the CLASS trial, some might reasonably be left with additional uncertainties about the integrity of the conduct of the SUCCESS-I, CONDOR, and GI-REASONS trials.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Event rates from the CONDOR trial for the primary composite outcome and its components.<sup><a href="#ref-30">30</a></sup></h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34243e1068 class=n-a></a><thead><a name=d34243e1070 class=n-a></a><tr><a name=d34243e1072 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e1074 class=n-a></a></th><th align=left colspan=1 rowspan=1><a name=d34243e1076 class=n-a></a>Celecoxib<br class=br>(n = 2,238)</th><th align=left colspan=1 rowspan=1><a name=d34243e1081 class=n-a></a>Diclofenac slow release<br class=br>plus omeprazole (n = 2,246)</th></tr></thead><tbody><a name=d34243e1088 class=n-a></a><tr><a name=d34243e1090 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1092 class=n-a></a>Primary composite outcome: clinically-significant<br class=br>events throughout the GI tract<sup><a href="#note_1">*</a></sup></td><td colspan=1 rowspan=1><a name=d34243e1100 class=n-a></a>20 (0.894%)</td><td colspan=1 rowspan=1><a name=d34243e1103 class=n-a></a>81 (3.606%)</td></tr><tr><a name=d34243e1107 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1109 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Clinically-significant anemia<sup><a href="#note_2">^</a></sup> of presumed occult<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;GI origin, including possible SB blood loss</td><td colspan=1 rowspan=1><a name=d34243e1118 class=n-a></a>10 (0.447%)</td><td colspan=1 rowspan=1><a name=d34243e1121 class=n-a></a>53 (2.360%)</td></tr><tr><a name=d34243e1125 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1127 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Clinically-significant anemia<sup><a href="#note_2">^</a></sup> with a defined GI<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;lesion judged to be the cause</td><td colspan=1 rowspan=1><a name=d34243e1136 class=n-a></a>5 (0.223%)</td><td colspan=1 rowspan=1><a name=d34243e1139 class=n-a></a>24 (1.069%)</td></tr><tr><a name=d34243e1143 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1145 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GD ulcer or erosions</td><td colspan=1 rowspan=1><a name=d34243e1148 class=n-a></a>5 (0.223%)</td><td colspan=1 rowspan=1><a name=d34243e1151 class=n-a></a>20 (0.890%)</td></tr><tr><a name=d34243e1155 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1157 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Early gastric cancer</td><td colspan=1 rowspan=1><a name=d34243e1160 class=n-a></a>0</td><td colspan=1 rowspan=1><a name=d34243e1163 class=n-a></a>1 (0.045%)</td></tr><tr><a name=d34243e1168 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1170 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lower GI bleeding<sup><a href="#note_3">#</a></sup></td><td colspan=1 rowspan=1><a name=d34243e1176 class=n-a></a>0</td><td colspan=1 rowspan=1><a name=d34243e1179 class=n-a></a>1 (0.045%)</td></tr><tr><a name=d34243e1183 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1185 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lower GI ulcer or erosions</td><td colspan=1 rowspan=1><a name=d34243e1188 class=n-a></a>0</td><td colspan=1 rowspan=1><a name=d34243e1191 class=n-a></a>2 (0.089%)</td></tr><tr><a name=d34243e1195 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1197 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Acute GI hemorrhage of unknown origin, including<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;presumed SB hemorrhage</td><td colspan=1 rowspan=1><a name=d34243e1202 class=n-a></a>1 (0.045%)</td><td colspan=1 rowspan=1><a name=d34243e1205 class=n-a></a>0</td></tr><tr><a name=d34243e1209 class=n-a></a><td colspan=3 rowspan=1><a name=d34243e1211 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Identical rates for the following components of the primary composite outcome: GD hemorrhage;<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;gastric outlet obstruction; GD, SB, or LB perforation; SB hemorrhage; and LB hemorrhage</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34243e1221 class=n-a></a><p id=d34243e1223> Data presented are number (percentage) of patients in each group and come from Table 2 of the CONDOR trial.<sup><a href="#ref-30">30</a></sup></p><p id=d34243e1229>GD indicates gastroduodenal; GI, gastrointestinal; LB, large-bowel; SB, small-bowel.</p><p id=note_1>*The primary composite outcome included: gastroduodenal, small-bowel, or large-bowel hemorrhage; acute gastrointestinal hemorrhage of unknown origin, including presumed small-bowel hemorrhage; gastroduodenal, small-bowel, or large-bowel perforation; gastric outlet obstruction; clinically significant anemia with a defined gastrointestinal lesion judged to be the cause; and clinically-significant anemia of presumed occult gastrointestinal origin, including possible small-bowel blood loss.</p><p id=note_2>^Clinically-significant anemia was defined in the protocol as a decrease in hemoglobin by 2 g/dL or more or a drop in hematocrit of 10% or more.</p><p id=note_3><sup>#</sup>One patient in the diclofenac slow release plus omeprazole group was found to have bleeding angiodysplasia in the colon.</p></div></div></div><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. Event rates from the GI-REASONS trial for the primary composite outcome and its components.<sup><a href="#ref-31">31</a></sup></h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34243e1260 class=n-a></a><thead><a name=d34243e1262 class=n-a></a><tr><a name=d34243e1264 class=n-a></a><th colspan=1 rowspan=1><a name=d34243e1266 class=n-a></a></th><th align=left colspan=1 rowspan=1><a name=d34243e1268 class=n-a></a>Celecoxib<sup><a href="#note_4">*</a></sup><br class=br>(n = 4,035)</th><th align=left colspan=1 rowspan=1><a name=d34243e1276 class=n-a></a>Nonselective NSAID<sup><a href="#note_4">*</a></sup><br class=br>(n = 4,032)</th></tr></thead><tbody><a name=d34243e1286 class=n-a></a><tr><a name=d34243e1288 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1290 class=n-a></a>Primary composite outcome: clinically-significant<br class=br>upper and/or lower GI events<sup><a href="#note_5">^</a></sup></td><td colspan=1 rowspan=1><a name=d34243e1298 class=n-a></a>54 (1.338%)</td><td colspan=1 rowspan=1><a name=d34243e1301 class=n-a></a>98 (2.431%)</td></tr><tr><a name=d34243e1305 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1307 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Clinically-significant anemia<sup><a href="#note_6">#</a></sup> of presumed<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;occult GI origin, including possible SB blood<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;loss</td><td colspan=1 rowspan=1><a name=d34243e1318 class=n-a></a>44 (1.090%)</td><td colspan=1 rowspan=1><a name=d34243e1321 class=n-a></a>75 (1.860%)</td></tr><tr><a name=d34243e1325 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1327 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Symptomatic ulcers<sup><a href="#note_7">+</a></sup></td><td colspan=1 rowspan=1><a name=d34243e1333 class=n-a></a>0</td><td colspan=1 rowspan=1><a name=d34243e1336 class=n-a></a>5 (0.124%)</td></tr><tr><a name=d34243e1340 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1342 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;LB hemorrhage</td><td colspan=1 rowspan=1><a name=d34243e1345 class=n-a></a>3 (0.074%)</td><td colspan=1 rowspan=1><a name=d34243e1348 class=n-a></a>6 (0.149%)</td></tr><tr><a name=d34243e1352 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1354 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Clinically-significant anemia<sup><a href="#note_6">#</a></sup> with a defined GI<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;lesion judged to be the cause</td><td colspan=1 rowspan=1><a name=d34243e1363 class=n-a></a>4 (0.099%)</td><td colspan=1 rowspan=1><a name=d34243e1366 class=n-a></a>6 (0.149%)</td></tr><tr><a name=d34243e1371 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1373 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Acute GI hemorrhage of unknown origin,<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;including presumed SB hemorrhage</td><td colspan=1 rowspan=1><a name=d34243e1378 class=n-a></a>1 (0.025%)</td><td colspan=1 rowspan=1><a name=d34243e1381 class=n-a></a>3 (0.074%)</td></tr><tr><a name=d34243e1385 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1387 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;GD hemorrhage</td><td colspan=1 rowspan=1><a name=d34243e1390 class=n-a></a>0</td><td colspan=1 rowspan=1><a name=d34243e1393 class=n-a></a>2 (0.050%)</td></tr><tr><a name=d34243e1397 class=n-a></a><td colspan=1 rowspan=1><a name=d34243e1399 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Gastric outlet obstruction</td><td colspan=1 rowspan=1><a name=d34243e1402 class=n-a></a>1 (0.025%)</td><td colspan=1 rowspan=1><a name=d34243e1405 class=n-a></a>0</td></tr><tr><a name=d34243e1409 class=n-a></a><td colspan=3 rowspan=1><a name=d34243e1411 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Identical rates for the following components of the primary composite outcome: SB<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;hemorrhage; SB obstruction; GD, SB, or LB perforation</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34243e1421 class=n-a></a><p id=d34243e1423> Data presented are number (percentage) of patients in each group and come from Table 1 from the GI-REASONS trial.<sup><a href="#ref-31">31</a></sup></p><p id=d34243e1429>GD indicates gastroduodenal; GI, gastrointestinal; LB, large-bowel; SB, small-bowel.</p><p id=note_4>*The trial allowed dose titration in each group and unrestricted medication selection and switching within the nonselective NSAID group (switching between the groups was not allowed, however). The celecoxib dose most commonly prescribed initially was 200 mg daily (90%). The nonselective NSAIDs included meloxicam (average dose 13.0 mg), naproxen (average dose 819.8 mg), nabumetone (average dose 1,089.0 mg), diclofenac (average dose 124.4 mg), ibuprofen (average dose 1,453.2 mg), and etodolac (average dose 709.2 mg).</p><p id=note_5>^The primary composite outcome included: gastroduodenal, small-bowel, or large-bowel hemorrhage; acute gastrointestinal hemorrhage of unknown origin, including presumed small-bowel hemorrhage; gastroduodenal, small-bowel, or large-bowel perforation; gastric outlet or small-bowel obstruction; symptomatic ulcers; clinically significant anemia with a defined gastrointestinal lesion judged to be the cause; clinically-significant anemia of presumed occult gastrointestinal origin including possible small-bowel blood loss.</p><p id=note_6><sup>#</sup>Clinically-significant anemia was defined in the protocol as a decrease in hemoglobin by 2 g/dL or more or a drop in hematocrit of 10% or more.</p><p id=note_7><sup>+</sup>Ulcers without complications, presenting with dyspepsia and having endoscopic or standard radiograph evidence of a gastric ulcer and/or duodenal ulcer.</p></div></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e1456>Remonstrance and reproach regarding rosiglitazone</h2><div class=section><a name=d34243e1459 class=n-a></a><h3 class=section-title>There is no way to sugarcoat it (nor should one attempt to do so)…</h3><p class="" id=d34243e1464>Rosiglitazone (Avandia<sup>®</sup>) provides us with yet another troubling example.<sup><a href="#ref-32">32</a>–<a href="#ref-43">43</a></sup> When John Buse (a physician researcher from the University of North Carolina at Chapel Hill) raised concern over the cardiovascular risk of rosiglitazone starting in 1999, the parent company of the drug took considerable efforts to try to silence him, including complaining to his superiors and threatening legal action. This ultimately ended in the U.S. Senate Committee on Finance (USSCoF) getting involved. The USSCoF eventually determined the actions of the parent company amounted to “intimidation,” and the USSCoF review of the matter is indeed telling: <div class=list><a name=d34243e1476 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e1482><span class=label></span> “<i>The effect of silencing this criticism is, in our opinion, extremely serious. At a July 30, 2007, safety panel on Avandia, FDA scientists presented an analysis estimating that Avandia caused approximately 83,000 excess heart attacks since coming on the market. Had GSK considered Avandia’s increased cardiovascular risk more seriously when the issue was first raised in 1999 by Dr. Buse, instead of trying to smother an independent medical opinion, some of these heart attacks may have been avoided</i>.”<sup><a href="#ref-32">32(p2)</a></sup></p></li></ul></div> </p><p class="" id=d34243e1494>Furthermore, additional internal company documents show more duplicitous behavior surrounding rosiglitazone (<a href="#f4">Figure 4</a>).<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup></p><div class="fig panel clearfix"><a name=f4 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure4.gif"><img alt="b0794328-9657-49d0-a52d-73caf908a0f9_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/7887/b0794328-9657-49d0-a52d-73caf908a0f9_figure4.gif"></a><div class=caption><h3>Figure 4. Sampling of internal company documents that are now a matter of public record (after being released by the U.S. Senate Committee on Finance) discussing rosiglitazone (Avandia<sup>®</sup>).<sup><a href="#ref-34">34</a></sup></h3><p id=d34243e1522>H-H indicates head-to-head trial; RSG, rosiglitazone. The images from pages 21 and 22 are from a consecutive email chain.</p></div></div><p class="" id=d34243e1529>Once again, the story does not end there. In 2007, Steven Nissen and Kathy Wolski sought to publish a meta-analysis of 42 studies on rosiglitazone in <i>NEJM</i>; however, one day after they submitted it to <i>NEJM</i>, Steve Haffner – one of the pre-publication peer reviewers and also a consultant for GlaxoSmithKline (GSK) – leaked the pre-publication manuscript to GSK in a fax marked “confidential” and “urgent.”<sup><a href="#ref-35">35(p5)</a></sup> This unethically leaked manuscript was then disseminated within GSK, and a GSK statistician attempting to find deficiencies in the Nissen and Wolski meta-analysis ultimately found “there is no statistical reason for disregarding the findings as presented.”<sup><a href="#ref-35">35(p6)</a></sup></p><p class="" id=d34243e1546>What exactly did the Nissen and Wolski meta-analysis find? Compared to the control group (defined in their meta-analysis as those who received either placebo or other medications used to treat diabetes), those who received rosiglitazone experienced significantly more MIs, with an odds ratio (OR) of 1.43 (95% CI, 1.03 – 1.98; P = 0.03).<sup><a href="#ref-36">36</a></sup> Nissen and Wolski also assessed death from cardiovascular causes, finding an OR of 1.64 (95% CI, 0.98 – 2.74; P = 0.06).<sup><a href="#ref-36">36</a></sup></p><p class="" id=d34243e1556>GSK and the FDA had also conducted their own meta-analyses, both of which were consistent with the findings in the Nissen and Wolski meta-analysis.<sup><a href="#ref-35">35</a></sup> In a concerned email to company executives on May 8, 2007, Moncef Slaoui, the head of research at GSK, spoke of the meta-analyses: <div class=list><a name=d34243e1562 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e1568><span class=label></span> <i>“-FDA, Nissen and GSK all come to a comparable conclusion regarding increased risk for ischemic events, ranging from 30% to 43%!</i></p></li><li><p id=d34243e1577><span class=label></span> <i>-FDA and Nissen (but no final data from GSK date</i> [sic]<i>) reach the conclusion of an HR for death (CHF + IHD) of 1.72 or 1.75!”</i><sup><a href="#ref-35">35(p164)</a></sup></p></li></ul></div> </p><p class="" id=d34243e1590>Despite this, when the Nissen and Wolski meta-analysis was published online on May 21, 2007, GSK responded the same day with the following: “GSK strongly disagrees with the conclusions reached in the <i>NEJM</i> article, which are based on incomplete evidence and methodology that the author admits has significant limitations.”<sup><a href="#ref-35">35(p173)</a></sup> This press release is in rather obvious contrast to internal discussions.</p><p class="" id=d34243e1600>Also of note, 27 of the 42 studies included in the Nissen and Wolski meta-analysis were unpublished but available to them as a result of litigation surrounding another drug manufactured by GSK (one of the 27 unpublished studies is also available through the FDA, as it was submitted to the FDA as part of the approval process for rosiglitazone).<sup><a href="#ref-36">36</a></sup> Nissen and Wolski updated their meta-analysis in 2010, which now included a total of 56 trials and importantly included the RECORD trial, an open-label, randomized, controlled trial that is still shrouded in some controversy.<sup><a href="#ref-35">35</a>,<a href="#ref-37">37</a>–<a href="#ref-42">42</a></sup> The 2010 meta-analysis included 36 unpublished trials (again with one trial also being available through the FDA) and 20 published trials.<sup><a href="#ref-41">41</a></sup> The effect estimate for MI (OR, 1.28; 95% CI, 1.02 – 1.63; P = 0.04) was similar, albeit somewhat less than that seen in the 2007 meta-analysis; with exclusion of the RECORD trial, the effect estimate increased (OR, 1.39; 95% CI, 1.02 – 1.89; P = 0.04) and more closely approximated the 2007 findings.<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a>,<a href="#ref-41">41</a></sup></p><p class="" id=d34243e1630>Briefly, interim results from the RECORD trial (which was originally planned to run until 2009) were published in 2007 shortly after Nissen and Wolski’s 2007 meta-analysis.<sup><a href="#ref-35">35</a>,<a href="#ref-37">37</a></sup> However, it appears GSK made this decision unilaterally, as opposed to leaving that decision in the hands of the steering committee (SC).<sup><a href="#ref-35">35</a></sup> A GSK employee is also on record reiterating the force with which GSK would pursue the matter with the SC if necessary: <div class=list><a name=d34243e1643 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e1649><span class=label></span> <i>“[I]f the SC believe that publishing interim data will fatally damage their ability to bring the study to a completion- Frank and I will bring that opinion with reasons back to GSK, before pursuing the line- that a decision has been made- live with it”</i>.<sup><a href="#ref-35">35(p184)</a></sup></p></li></ul></div> </p><p class="" id=d34243e1661>The SC was convinced, however, and the unplanned interim analysis was published. However, as the pre-publication manuscript was being sent amongst the primary authors, one author noted: “The HR ratio [sic] (and 95% CI) for MI in RECORD is not inconsistent with Nissen’s – and he had more events; what’s to stop him adding the events from RECORD to his meta-analysis and re-enforcing his view?”<sup><a href="#ref-35">35(p197)</a></sup> (note this is exactly what happened in the updated meta-analysis published in 2010). This same author also wrote in the same email: “[m]anuscript looks to me to play down 239% INCREASE in HF. I have taken the liberty of doing some rewording.”<sup><a href="#ref-35">35(p197)</a></sup> Though one is glad to see the concern about downplaying an increase in heart failure, the tone of the manuscript was still far too strong, as evidenced by the pre-publication editorial and peer review process. Though there is unavoidable uncertainty that accompanies interpretation of an unplanned interim analysis, the published data were not inconsistent with the 2007 Nissen and Wolski meta-analysis.<sup><a href="#ref-35">35</a>,<a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup> However, the interim analysis was too underpowered to determine anything robustly, a fact that USSCoF documents suggest GSK knew.<sup><a href="#ref-35">35</a>,<a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup></p><p class="" id=d34243e1692>One peer reviewer plainly noted that the data “are inconclusive about the question of increased risk in the rosiglitazone arm,”<sup><a href="#ref-35">35(p201)</a></sup> and an editor for <i>NEJM</i> noted: <div class=list><a name=d34243e1701 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e1707><span class=label></span> “<i>This reviewer, along with other reviewers, asks that you modify the language in multiple locations in the manuscript to tone down your conclusions. This is especially important given that this is an unplanned interim analysis of an ongoing trial, a fact that introduces additional uncertainty. Please note that, in the opinion of all readers, the data that you present are completely compatible with the results of the meta-analysis by Nissen and the meta-analysis for myocardial ischemic events posted on the GSK Web site</i>.”<sup><a href="#ref-35">35(p201)</a></sup></p></li><li><p id=d34243e1721><span class=label></span> and</p></li><li><p id=d34243e1729><span class=label></span> “<i>The editors feel strongly that your data do not support the statement that the RECORD results for MI contradict the Nissen meta-analysis; this statement must be removed or modified</i>.”<sup><a href="#ref-35">35(p202)</a></sup></p></li></ul></div> </p><p class="" id=d34243e1741>Upon making the requisite changes, the interim RECORD trial results were published in <i>NEJM</i> (electronic publication in June 2007, print publication in July 2007); however, it was accompanied by three editorials, all of which expressed reservations about the publication, including noting it was underpowered, possibly suffered from incomplete event ascertainment, and did not really provide any assurance of the safety of rosiglitazone.<sup><a href="#ref-37">37</a>–<a href="#ref-40">40</a></sup></p><p class="" id=d34243e1753>A purportedly independent reevaluation of the RECORD trial cardiovascular outcomes data was also recently published by a team from the Duke Clinical Research Institute (DCRI).<sup><a href="#ref-42">42</a></sup> Although it essentially upheld the interim RECORD analysis, one notes that GSK was allowed to prepare the materials for the reanalysis, and “[d]espite a concerted effort to obtain additional information, only a modest amount of additional person-years of follow-up was obtained (328 person-years)” by the DCRI team, which was mostly “about vital status and not nonfatal MIs or strokes.”<sup><a href="#ref-42">42(p247)</a></sup> To give context, there were a total of 25,833 person-years of follow-up for mortality and 23,692 person-years of follow-up for the composite of cardiovascular death, MI, or stroke.<sup><a href="#ref-42">42</a></sup></p><p class="" id=d34243e1767>The aforementioned role that GSK had in the DCRI team’s analysis raises difficult questions. The DCRI team can only operate on the data to which they had access, which was overwhelmingly prepared and provided by GSK. Since Buse first raised concerns in 1999, the above seems to make it clear that GSK’s history with rosiglitazone does not reflect one of scientific integrity or transparency. In its concluding remarks, the 2010 USSCoF document notes:<div class=list><a name=d34243e1769 class=n-a></a><ul style="list-style-type: none"><li><p id=d34243e1775><span class=label></span> “<i>The totality of evidence suggests that GSK was aware of the possible cardiac risks associated with Avandia years before such evidence became public. Several years prior to Nissen’s study, it can be argued that GSK was on notice that Avandia may have problems. Based on this knowledge, GSK had a duty to sufficiently warn patients and the FDA of its concerns in a timely manner. Instead, GSK executives intimidated independent physicians, focused on strategies to minimize findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that the rival drug ACTOS (pioglitazone) might reduce cardiovascular risk. In recent years, pharmaceutical companies have committed acts that forced them to pay the largest criminal fines in American history</i>.”<sup><a href="#ref-35">35(p15)</a></sup></p></li></ul></div> </p><p class="" id=d34243e1787>Additionally, even if one were to accept the RECORD trial results, the 2010 meta-analysis by Nissen and Wolski that included the RECORD trial still stands, and there is still the concern over the increased incidence of heart failure in the RECORD data, so it remains clear the RECORD data ultimately do not resolve concerns about rosiglitazone.</p><p class="" id=d34243e1790>In 2012, GSK officially pled guilty to, among other things, failing to report safety data about rosiglitazone to the FDA.<sup><a href="#ref-43">43</a></sup></p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e1800>The off-putting case of oseltamivir</h2><div class=section><a name=d34243e1803 class=n-a></a><h3 class=section-title>Feel sick yet?</h3><p class="" id=d34243e1808>On July 14, 2009, Japanese pediatrician Keiji Hayashi astutely pointed out a problem with the then-current Cochrane review on oseltamivir (Tamiflu<sup>®</sup>) in healthy adults.<sup><a href="#ref-44">44</a></sup> Specifically, Hayashi noted the Cochrane review based its conclusion about the effect of oseltamivir on lower respiratory tract complications on a 2003 meta-analysis of ten randomized controlled trials (RCTs) by Kaiser and colleagues, but only two of the trials were published in the peer-reviewed literature.<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup> Hayashi requested the Cochrane group analyze all the data independently. The Cochrane group promptly attempted to do this, but what followed was nothing short of a farce.<sup><a href="#ref-44">44</a>,<a href="#ref-47">47</a>–<a href="#ref-60">60</a></sup> Roche, who manufactures oseltamivir, stymied the authors from obtaining the data from the eight unpublished RCTs, and because the Cochrane authors were unable to obtain the data from the eight unpublished RCTs, they accordingly changed their conclusion in their updated review, which per Cochrane rules was due six months after Hayashi’s critique.<sup><a href="#ref-44">44</a>,<a href="#ref-47">47</a>–<a href="#ref-51">51</a></sup> During their continued pursuit of the trial data, the Cochrane authors also came to realize that they would have to dig far deeper than they had anticipated, ultimately resulting in them requesting the original full clinical study reports (CSRs) from Roche; the plight is chronicled in great detail in <i>The BMJ</i>, the Cochrane reviews, and <i>PLoS Medicine</i>.<sup><a href="#ref-52">52</a>–<a href="#ref-60">60</a></sup> <i>The BMJ</i>’s website also has extensive details, including a timeline and catalogued correspondence.<sup><a href="#ref-44">44</a>,<a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup> Fiona Godlee (Editor-in-Chief of <i>The BMJ)</i>, Tom Jefferson and Peter Doshi (two authors of the Cochrane review, with Jefferson as lead author), and others fiercely pursued the issue. As a result of this endeavor, <i>The BMJ</i> also ultimately started the “Open Data” campaign on October 29, 2012, with the first campaign being the “Tamiflu campaign.”<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup></p><p class="" id=d34243e1885>In late 2013, Roche finally made 77 minimally-redacted CSRs available to Jefferson and his colleagues, and they were subsequently able to undertake an unprecedented review of CSRs that required herculean effort. Their updated review on the effects of oseltamivir in healthy adults and children was finally published in 2014 (their designation of “previously healthy” allowed chronic illnesses such as asthma, diabetes, or hypertension, but did not allow conditions with greater potential to impact immune system functioning, such as malignancy or HIV).<sup><a href="#ref-59">59</a></sup> The reviewers ultimately assessed 23 oseltamivir trials in Stage 1 of the review (where Jefferson and colleagues assessed for appropriate trial design and reliability and completeness of data); as a result, three of these 23 trials were ultimately excluded from Stage 2 of the review (the full analysis following Cochrane standards). Stage 2 included 20 trials amounting to 9,623 patients in total (6,574 in treatment trials and 3,049 in prophylaxis trials): 11 trials were on the treatment of adults, four were on the treatment of children, two were on prophylaxis in adults, two were on prophylaxis of the elderly, and one was on prophylaxis in households. The results are not terribly flattering for oseltamivir.<sup><a href="#ref-59">59</a></sup></p><p class="" id=d34243e1895>To give a brief overview of the results, oseltamivir was found to reduce symptom duration by about 16.8 hours in adults (95% CI, 8.4 – 25.1 hours; P &lt; 0.0001), amounting to roughly 0.70 days (95% CI, 0.35 – 1.05 days). In children, no beneficial effect was noted overall. When stratifying children by presence of asthma, children with asthma did not benefit, but otherwise healthy children experienced a reduction in symptom duration by about 29.4 hours (95% CI, 11.8 – 47.0 hours; P = 0.0011), amounting to roughly 1.21 days (95% CI, 0.49 – 1.96 days); however, the results in healthy children are based on a single trial with 669 participants, and the results in children with asthma are based on two trials with a total of 660 participants between the two trials.</p><p class="" id=d34243e1898>The authors found no beneficial effect of oseltamivir on hospitalizations, serious complications (pneumonia was considered individually and will be discussed below), bronchitis, sinusitis, or otitis media.</p><p class="" id=d34243e1902>Pneumonia was considered as an individual outcome. Noteworthy issues with pneumonia as an endpoint included it being a self-reported, investigator-mediated, unverified diagnosis, and the documentation was at times weakly regimented. However, with this understanding, the authors found an absolute risk difference (ARD) of 1.00% in adults (95% CI, 0.22% – 1.49%; risk ratio [RR], 0.55; 95% CI, 0.33 – 0.90; P = 0.017), which means 100 adults would have to be treated with oseltamivir to prevent one case of pneumonia (number needed to treat to benefit one person [NNTB], 100; 95% CI, 67 – 451). However, in the analysis limited to more detailed documentation of pneumonia (which had just over one-third the amount of patient data that the less specific documentation method had), no statistically significant benefit was found for prevention of pneumonia. No study reported the effects of oseltamivir on pneumonia confirmed by radiography (a rather notable shortcoming of the available trial data), and there was no apparent effect on pneumonia in children whatsoever.</p><p class="" id=d34243e1905>For adult prophylaxis, the review found that oseltamivir helped reduce symptomatic influenza with an NNTB of 33 (95% CI, 26 to 55; ARD, 3.05%; 95% CI, 1.83% – 3.88%; RR, 0.45; 95% CI, 0.30 – 0.67; P = 0.000091). Effects of prophylaxis in children are not reported, as no trials of prophylaxis in children were included in Stage 2.</p><p class="" id=d34243e1908>Adverse effects varied between active treatment and prophylaxis. If taking active treatment, nausea occurred significantly more often in adults with a number needed to treat to harm one person (NNTH) of 28 (95% CI, 14 – 112; ARD, 3.66%; 95% CI, 0.90% – 7.39%; RR, 1.57; 95% CI, 1.14 – 2.15; P = 0.0051); vomiting also occurred significantly more in adults with an NNTH of 22 (95% CI, 14 – 42; ARD, 4.56%; 95% CI, 2.39% – 7.58%; RR, 2.43; 95% CI, 1.75 – 3.38; P &lt; 0.00001). In children, nausea was not significantly more common, but vomiting was with an NNTH of 19 (95% CI, 10 – 57; ARD, 5.34%; 95% CI, 1.75% – 10.29%; RR, 1.70; 95% CI, 1.23 – 2.35; P = 0.0014). If taking prophylaxis, headache (ARD, 3.15%; 95% CI, 0.88% – 5.78%; NNTH, 32; 95% CI, 18 – 115; RR, 1.18; 95% CI, 1.05 – 1.33; P = 0.0053) and nausea (ARD, 4.15%; 95% CI, 0.86% – 9.51%; NNTH, 25; 95% CI, 11 – 116; RR, 1.96; 95% CI, 1.20 – 3.20; P = 0.0068) both occurred significantly more often in adults while taking the prophylactic regimen. Psychiatric side effects while on prophylactic treatment approached significance (P = 0.062) and crossed the threshold of significance when the authors pooled on- and off-treatment events with an NNTH of 94 (95% CI, 36 – 1,538; ARD, 1.06%; 95% CI, 0.07% – 2.76%; RR, 1.80; 95% CI, 1.05 – 3.08; P = 0.031).</p><p class="" id=d34243e1911>Most admirably, those wishing to scrutinize the data for themselves have open access to the entirety of the data.<sup><a href="#ref-61">61</a></sup> The full Cochrane review is now freely available (in 2013, the Cochrane Collaboration committed to making its reviews open-access one year after they are published), and an abridged version of the review has open-access availability as a separate article published in <i>The BMJ</i>.<sup><a href="#ref-59">59</a>,<a href="#ref-62">62</a></sup></p><p class="" id=d34243e1927>An individual-patient-data meta-analysis (IPD MA) of nine Roche-sponsored oseltamivir trials including 4,328 adult patients being treated for influenza was published in <i>Lancet</i> not too long after the updated Cochrane review was published.<sup><a href="#ref-63">63</a></sup> Although the methods are not as thorough or transparent as the Cochrane review, the primary outcome in the <i>Lancet</i> IPD MA was reduction in time to alleviation of symptoms, and for the full intention-to-treat (ITT) population, this outcome was a median of 17.8 hours (95% CI, 9.3 to 27.1 hours; time ratio, 0.85; 95% CI, 0.80 – 0.90; P &lt; 0.0001), which is quite similar to the respective findings of the Cochrane review. In the analysis limited to patients with laboratory confirmation of influenza infection (PWCIIs), the reduction in time to alleviation of symptoms was 25.2 hours (95% CI, 16.0 to 36.2 hours; time ratio, 0.79; 95% CI, 0.74 – 0.85; P &lt; 0.0001). Although this primary outcome was largely consistent with the findings of the Cochrane review, two other analyses – lower respiratory tract complications and hospitalizations – were emphasized by the study’s authors, and these findings were not consistent with those of the Cochrane review. In the analysis of PWCIIs, lower respiratory tract complications “requiring” antibiotics were lower among those receiving oseltamivir, with an ARD of 3.83% (95% CI, 2.18% – 5.05%; RR, 0.56; 95% CI, 0.42 – 0.75; P = 0.0001), translating to an NNTB of 27 (95% CI, 20 – 46). However, this was overwhelmingly due to cases of acute bronchitis (representing 81.71% of all the events in this outcome), a condition for which antibiotics are not indicated unless the etiology is <i>Bordetella pertussis</i>, which is uncommon.<sup><a href="#ref-64">64</a>–<a href="#ref-66">66</a></sup> (Acute exacerbations of chronic bronchitis sometimes do require antibiotics, but this is not what the authors reference in their meta-analysis.) In the full ITT population, the ARD for lower respiratory tract complications was attenuated to 2.98% (95% CI, 1.65% – 4.00%; RR, 0.62; 95% CI, 0.49 – 0.79; P = 0.0001), with a corresponding NNTB of 34 (95% CI, 25 – 61), and the majority of the events (79.76%) were once again cases of acute bronchitis.</p><p class="" id=d34243e1950>The authors also reported a lower rate of pneumonia in the PWCIIs, with an ARD, 1.00% (95% CI, 0.27% – 1.35%; RR, 0.40; 95% CI, 0.19 – 0.84; P = 0.015) and corresponding NNTB of 101 (95% CI, 75 – 376; minor apparent discrepancies in NNTBs and ARDs are the effect of rounding the ARDs to two decimal places). In the full ITT population, the ARD was 1.13% (95% CI, 0.62% – 1.40%; RR, 0.34; 95% CI, 0.18 – 0.64; P = 0.0009), with a corresponding NNTB of 89 (95% CI, 72 – 163). However, cases of pneumonia were again based on “participant report and the investigator’s clinical judgment” without radiographic confirmation.<sup><a href="#ref-63">63(p1731)</a></sup> Furthermore, given the issues surrounding “pneumonia” as an outcome in the trials in both this analysis and the Cochrane review, one also has to question the rigor with which acute bronchitis was assessed, and the same can be said for lower respiratory tract complications “requiring” antibiotics in general. Indeed, the <i>Lancet</i> analysis provides no clear definition for such outcomes, which were also based on “participant report and the investigator’s clinical judgment,” and there appear to have been no criteria to confirm a bacterial infection or the “need” for antibiotics.<sup><a href="#ref-63">63(p1731)</a></sup></p><p class="" id=d34243e1964>The other analysis emphasized by the <i>Lancet</i> IPD MA was a 1.06% ARD (95% CI, 0.32% – 1.40%; RR, 0.37; 95% CI, 0.17 – 0.81; P = 0.013) for being admitted to the hospital for any reason, translating to an NNTB of 94 (95% CI, 72 – 312); however, the reasons for admission were reportedly too varied to detect any pattern. Here again, we seem to be lacking a desirable granularity and clarity (in spite of the IPD MA approach). In the full ITT population, there was no significant difference in hospitalization.</p><p class="" id=d34243e1970>With respect to adverse effects from oseltamivir, the <i>Lancet</i> IPD MA also found increases in nausea in both the PWCIIs (ARD, 3.93%; 95% CI, 1.57% – 7.00%; NNTH, 25; 95% CI, 14 – 63; RR, 1.60; 95% CI, 1.24 – 2.07; P = 0.0003) and the full safety population (ARD, 3.69%; 95% CI, 1.79% – 6.09%; NNTH, 27; 95% CI, 16 – 56; RR, 1.60; 95% CI, 1.29 – 1.99; P &lt; 0.0001). It also found increases in vomiting in both the PWCIIs (ARD, 6.31%; 95% CI, 3.50% – 10.29%; NNTH, 15; 95% CI, 9 – 28; RR, 3.00; 95% CI, 2.11 – 4.26; P &lt; 0.0001) and the full safety population (ARD, 4.70%; 95% CI, 2.73% – 7.33%; NNTH, 21; 95% CI, 13 – 36; RR, 2.43; 95% CI, 1.83 – 3.23; P &lt; 0.0001). This review noted no significant increase in neurological or psychiatric outcomes in either population. There was an increase in “injuries and poisoning” in the full safety population (ARD, 0.49%; 95% CI, 0.02% – 1.98%; NNTH, 202; 95% CI, 50 – 5,990; RR, 3.37; 95% CI, 1.08 – 10.47; P = 0.036), but this was based on 15 events in the oseltamivir recipients and 4 events in the placebo recipients.</p><p class="" id=d34243e1976>IPD MA is a powerful analytical modality, and the Cochrane authors also requested individual patient data, but they never received it despite follow-up correspondence (see the “Rapid Responses” to the abridged version of the review published in <i>The BMJ</i><sup><a href="#ref-62">62</a></sup> and the catalogued correspondence with Roche<sup><a href="#ref-48">48</a></sup>). Even with individual patient data, the IPD MA published in <i>Lancet</i> finds only small and uncertain effects, and it is not as thorough or transparent as that of the Cochrane group with respect to methodology. Furthermore, as the Cochrane review authors note, analysis limited to PWCIIs is likely problematic, introducing bias (from demonstrated imbalances in the treatment groups when analyzing only PWCIIs) and limited generalizability (from variable availability of influenza tests, which themselves can suffer from variable accuracy).<sup><a href="#ref-59">59</a></sup> Additionally, one notes the <i>Lancet</i> IPD MA was, on the surface, funded by the independent Multiparty Group for Advice on Science (MUGAS) foundation (for example, this is the funding source reported in the abstract on PubMed); however, an unrestricted grant from Roche really funded the study. Although not transparently reflected on PubMed, this is admitted within the body of the meta-analysis (see the “Acknowledgements” section at the very end of the article and the “Role of the funding source” subsection at the end of the “Methods” section). The authors claim Roche merely provided funding and had no other involvement, but this still introduces an unavoidable degree of uncertainty, and this is not ameliorated by discovering that two of the four authors have significant conflicts of interest (with one of the authors being on the Board of Directors of Gilead Sciences, which, although not specified in the disclosures, holds the patent on oseltamivir).</p><p class="" id=d34243e1999>Although the current Cochrane review on oseltamivir is unprecedented in scale and even some of its methodology (i.e. reviewing individual CSRs), it represents a collective concerted effort to summarize the best-available research literature on oseltamivir in an unbiased manner, and it unequivocally represents the most robust, complete, and transparent assessment of the clinical trial evidence on oseltamivir.</p><p class="" id=d34243e2002>Putting all this aside, the deeply troubling and more important observation – which is seen in the research providing an overview of these issues<sup><a href="#ref-1">1</a>–<a href="#ref-6">6</a></sup> and which speaks to the core of this entire writing – is the utter lack of full publication and transparency. Hayashi made his critique in 2009. The updated Cochrane review could not be published until 2014 despite continual intensive efforts to gain access to the requisite data.</p><p class="" id=d34243e2012>This is a problem.</p><p class="" id=d34243e2016>Rather, it is a symptom, and the same symptoms are encapsulated in the aforementioned systematic reviews and other studies that collectively establish the indisputable and pervasive presence of these issues in the medical literature.<sup><a href="#ref-1">1</a>–<a href="#ref-6">6</a></sup> These symptoms signify a grave illness in medicine, one that can only be corrected with a unified effort to provide the remedy.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34243e2031>Conclusion</h2><div class=section><a name=d34243e2034 class=n-a></a><h3 class=section-title>Searching for the remedy</h3><p class="" id=d34243e2039>The International Committee of Medical Journal Editors’ requirement of <i>a priori</i> clinical trial registration in order to be considered for publication has failed to provide this remedy.<sup><a href="#ref-67">67</a>–<a href="#ref-72">72</a></sup> Similarly, ClinicalTrials.gov and the reporting mandate in Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA of 2007) have also failed, and the changes proposed in late 2014 by the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS) unfortunately do not provide any material assurance of rectifying these issues.<sup><a href="#ref-73">73</a>–<a href="#ref-86">86</a></sup> On the surface, the changes are desirable, as they call for an expansion in what exactly must be reported. Notably, however, the changes do nothing to address clinical trials that occurred before the FDAAA of 2007 initially went into effect; the changes are still reliant on the FDAAA of 2007, which has quite simply never been enforced; the changes would actually expand the responsibilities for enforcement even though there was a complete failure to enforce the FDAAA of 2007 in its original form; and the changes do not provide any explanation for the non-enforcement issue or any assurance of enforcement going forward.<sup><a href="#ref-73">73</a>–<a href="#ref-86">86</a></sup></p><p class="" id=d34243e2065>On the other hand, the AllTrials initiative (<a target=xrefwindow href="http://www.alltrials.net/" id=d34243e2067>www.alltrials.net</a>) – a joint initiative of (in alphabetic order): Bad Science, <i>The BMJ</i>, the Centre for Evidence-based Medicine, the Cochrane Collaboration, the James Lind Initiative, <i>PLoS</i>, and Sense About Science – has gained much momentum since its launch in 2013, and it continues to fight in this arena.<sup><a href="#ref-87">87</a>–<a href="#ref-86">89</a></sup> It is being led in the U.S. by Dartmouth’s Geisel School of Medicine and the Dartmouth Institute for Health Policy and Clinical Practice, with the official launch in the U.S. occurring just this year in late July.<sup><a href="#ref-87">87</a></sup> Likewise, <i>The BMJ</i> remains very active in this arena, and Doshi and colleagues’ Restoring Invisible and Abandoned Trials (RIAT) initiative remains active as well.<sup><a href="#ref-47">47</a>,<a href="#ref-90">90</a>–<a href="#ref-92">92</a></sup> The Institute of Medicine (IOM) and World Health Organization (WHO) also recently made explicit calls to improve these issues.<sup><a href="#ref-93">93</a>,<a href="#ref-94">94</a></sup> The remedy is long overdue, and we owe it to patients to come up with that remedy. Although this “case series” focuses heavily on industry (and with due cause), it must be noted that industry is not the only party at fault here; indeed, although not a novel finding, even the most recent appraisal of the failure of ClinicalTrials.gov and the FDAAA of 2007 shows that studies funded by governmental or academic institutions also suffer greatly from publication bias.<sup><a href="#ref-82">82</a></sup> Importantly, the AllTrials initiative, the activities of <i>The BMJ</i>, the RIAT initiative, and the calls of the IOM and WHO are not simply glittering generalities that ultimately lack substance – they all make concerted efforts to meaningfully address the issues, and contained within these efforts are suggested remedies. However, in order for these issues to be resolved, we still desperately need a unified voice from those within the scientific and medical community, and those outside the medical and scientific community should be a part of this as well. Publication bias and inadequate research transparency are scientifically and medically reprehensible and in violation of the basic ethical principles set forth in the World Medical Association’s Declaration of Helsinki.<sup><a href="#ref-95">95</a></sup> These issues have existed and gone unfettered for far too long. It is time to change that.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d34243e1 class=n-a></a><h2 class=main-title id=d34503>Competing interests</h2><p class=metadata-entry><a name=d34243e75 class=n-a></a><p id=d34243e77> Truly none, but in the interest of full disclosure, I am a current member of the U.S. Board of <i>BMJ</i> Fellows. I do not receive any compensation from <i>The BMJ</i> or anyone else as a result of this. I disclose this here since this article cites works published in <i>The BMJ</i> and ultimately draws attention to their efforts in combating issues with publication bias and inadequate research transparency.</p></p></div><div class=back-section><a name=d34243e1 class=n-a></a><h2 class=main-title id=d34505>Grant information</h2><p>The author declared that no grants/funding were involved in supporting this work.</p></div><div class=back-section><a name=d34243e2125 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d34787>References</h2><div class="section ref-list"><a name=d34243e2125 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d34243e2132 class=n-a></a>Dwan K, Gamble C, Williamson PR, <i> et al.</i>: Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. <i>PLoS One.</i> 2013; <b>8</b>(7): e66844. <a target=xrefwindow id=d34243e2143 href="http://www.ncbi.nlm.nih.gov/pubmed/23861749">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2146 href="http://dx.doi.org/10.1371/journal.pone.0066844">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3702538">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d34243e2159 class=n-a></a>Song F, Parekh S, Hooper L, <i> et al.</i>: Dissemination and publication of research findings: an updated review of related biases. <i>Health Technol Assess.</i> 2010; <b>14</b>(8): iii, ix-ix, 1–193. <a target=xrefwindow id=d34243e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/20181324">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2173 href="http://dx.doi.org/10.3310/hta14080">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d34243e2182 class=n-a></a>Hopewell S, Loudon K, Clarke MJ, <i> et al.</i>: Publication bias in clinical trials due to statistical significance or direction of trial results. <i>Cochrane Database Syst Rev.</i> 2009; (1): MR000006. <a target=xrefwindow id=d34243e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/19160345">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2193 href="http://dx.doi.org/10.1002/14651858.MR000006.pub3">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d34243e2202 class=n-a></a>Wieseler B, Wolfram N, McGauran N, <i> et al.</i>: Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. <i>PLoS Med.</i> 2013; <b>10</b>(10): e1001526. <a target=xrefwindow id=d34243e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/24115912">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2216 href="http://dx.doi.org/10.1371/journal.pmed.1001526">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3793003">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d34243e2229 class=n-a></a>Dwan K, Altman DG, Cresswell L, <i> et al.</i>: Comparison of protocols and registry entries to published reports for randomised controlled trials. <i>Cochrane Database Syst Rev.</i> 2011; (1): MR000031. <a target=xrefwindow id=d34243e2237 href="http://www.ncbi.nlm.nih.gov/pubmed/21249714">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2240 href="http://dx.doi.org/10.1002/14651858.MR000031.pub2">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d34243e2250 class=n-a></a>Chan AW, Hróbjartsson A, Haahr MT, <i> et al.</i>: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. <i>JAMA.</i> 2004; <b>291</b>(20): 2457–2465. <a target=xrefwindow id=d34243e2261 href="http://www.ncbi.nlm.nih.gov/pubmed/15161896">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2264 href="http://dx.doi.org/10.1001/jama.291.20.2457">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d34243e2273 class=n-a></a>Furberg CD: Effect of antiarrhythmic drugs on mortality after myocardial infarction. <i>Am J Cardiol.</i> 1983; <b>52</b>(6): 32C–36C. <a target=xrefwindow id=d34243e2281 href="http://www.ncbi.nlm.nih.gov/pubmed/6353896">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2284 href="http://dx.doi.org/10.1016/0002-9149(83)90629-X">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d34243e2293 class=n-a></a>Echt DS, Liebson PR, Mitchell LB, <i> et al.</i>: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. <i>N Engl J Med.</i> 1991; <b>324</b>(12): 781–788. <a target=xrefwindow id=d34243e2304 href="http://www.ncbi.nlm.nih.gov/pubmed/1900101">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2307 href="http://dx.doi.org/10.1056/NEJM199103213241201">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d34243e2316 class=n-a></a>The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. <i>N Engl J Med.</i> 1992; <b>327</b>(4): 227–233. <a target=xrefwindow id=d34243e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/1377359">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2327 href="http://dx.doi.org/10.1056/NEJM199207233270403">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d34243e2336 class=n-a></a>Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. <i>JAMA.</i> 1993; <b>270</b>(13): 1589–1595. <a target=xrefwindow id=d34243e2344 href="http://www.ncbi.nlm.nih.gov/pubmed/8371471">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2347 href="http://dx.doi.org/10.1001/jama.1993.03510130095038">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d34243e2356 class=n-a></a>Moore TJ: Deadly Medicine: Why Tens of Thousands of Patients Died in America’s Worst Drug Disaster. New York, NY: Simon &amp; Schuster, 1995. <a target=xrefwindow id=d34243e2358 href="https://books.google.co.in/books/about/Deadly_Medicine.html?id=7PYeAQAAIAAJ">Reference Source</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d34243e2368 class=n-a></a>Cowley AJ, Skene A, Stainer K, <i> et al.</i>: The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. <i>Int J Cardiol.</i> 1993; <b>40</b>(2): 161–166. <a target=xrefwindow id=d34243e2379 href="http://www.ncbi.nlm.nih.gov/pubmed/8349379">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2382 href="http://dx.doi.org/10.1016/0167-5273(93)90279-P">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d34243e2391 class=n-a></a>Turner EH, Matthews AM, Linardatos E, <i> et al.</i>: Selective publication of antidepressant trials and its influence on apparent efficacy. <i>N Engl J Med.</i> 2008; <b>358</b>(3): 252–260. <a target=xrefwindow id=d34243e2402 href="http://www.ncbi.nlm.nih.gov/pubmed/18199864">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2405 href="http://dx.doi.org/10.1056/NEJMsa065779">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d34243e2414 class=n-a></a>Melander H, Ahlqvist-Rastad J, Meijer G, <i> et al.</i>: Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. <i>BMJ.</i> 2003; <b>326</b>: 1171. <a target=xrefwindow id=d34243e2425 href="http://www.ncbi.nlm.nih.gov/pubmed/12775615">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2428 href="http://dx.doi.org/10.1136/bmj.326.7400.1171">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2432 href="http://www.ncbi.nlm.nih.gov/pmc/articles/156459">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d34243e2441 class=n-a></a>Vedula SS, Bero L, Scherer RW, <i> et al.</i>: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. <i>N Engl J Med.</i> 2009; <b>361</b>(20): 1963–1971. <a target=xrefwindow id=d34243e2452 href="http://www.ncbi.nlm.nih.gov/pubmed/19907043">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2455 href="http://dx.doi.org/10.1056/NEJMsa0906126">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d34243e2464 class=n-a></a>Vedula SS, Goldman PS, Rona IJ, <i> et al.</i>: Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin<sup>® </sup>litigation. <i>Trials.</i> 2012; <b>13</b>(136): 1–13. [Also: Additional file for Vedula <i>et al</i>. <i>Trials</i>. 2012; 13(136): 1–45]. <a target=xrefwindow id=d34243e2485 href="http://www.ncbi.nlm.nih.gov/pubmed/22888801">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2488 href="http://dx.doi.org/10.1186/1745-6215-13-136">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2491 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3439687">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d34243e2500 class=n-a></a>Vedula SS, Li T, Dickersin K: Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. <i>PLoS Med.</i> 2013; <b>10</b>(1): e1001378. <a target=xrefwindow id=d34243e2508 href="http://www.ncbi.nlm.nih.gov/pubmed/23382656">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2511 href="http://dx.doi.org/10.1371/journal.pmed.1001378">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3558476">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d34243e2524 class=n-a></a>Silverstein FE, Faich G, Goldstein JL, <i> et al.</i>: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. <i>JAMA.</i> 2000; <b>284</b>(10): 1247–1255. <a target=xrefwindow id=d34243e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/10979111">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2538 href="http://dx.doi.org/10.1001/jama.284.10.1247">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d34243e2547 class=n-a></a>Lu HL: Statistical reviewer briefing document for the advisory committee. 2011. Accessed/link verified August 24, 2011. <a target=xrefwindow id=d34243e2549 href="http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc">Reference Source</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d34243e2558 class=n-a></a>Goldkind L: Medical officer’s gastroenterology advisory committee briefing document. 2000. Accessed/link verified August 24, 2011. <a target=xrefwindow id=d34243e2560 href="http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf">Reference Source</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d34243e2569 class=n-a></a>Witter J: Celebrex capsules (celecoxib), NDA 20–998/S-009, medical officer review. 2000. Accessed/link verified August 24, 2011. <a target=xrefwindow id=d34243e2571 href="http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf">Reference Source</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d34243e2580 class=n-a></a>Wright JM, Perry TL, Bassett KL, <i> et al.</i>: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. <i>JAMA.</i> 2001; <b>286</b>(19): 2398–2400. <a target=xrefwindow id=d34243e2591 href="http://www.ncbi.nlm.nih.gov/pubmed/11712925">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2594 href="http://dx.doi.org/10.1001/jama.286.19.2398">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d34243e2603 class=n-a></a>Hrachovec JB, Mora M: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. <i>JAMA.</i> 2001; <b>286</b>(19): 2398; author reply 2399–2400. <a target=xrefwindow id=d34243e2611 href="http://www.ncbi.nlm.nih.gov/pubmed/11712924">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2614 href="http://dx.doi.org/10.1001/jama.286.19.2398">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d34243e2624 class=n-a></a>Silverstein F, Simon L, Faich G: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. <i>JAMA.</i> 2001; <b>286</b>(19): 2398; author reply 2399–2400. <a target=xrefwindow id=d34243e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/11712924">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2635 href="http://dx.doi.org/10.1001/jama.286.19.2398">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d34243e2644 class=n-a></a>Jüni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? <i>BMJ.</i> 2002; <b>324</b>(7349): 1287–1288. <a target=xrefwindow id=d34243e2652 href="http://www.ncbi.nlm.nih.gov/pubmed/12039807">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2655 href="http://dx.doi.org/10.1136/bmj.324.7349.1287">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1123260">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d34243e2667 class=n-a></a>Case 3:03-cv-01519-AET-TJB. Document 328-3. Available through the Public Access to Court Electronic Records (PACER) database: <a target=xrefwindow id=d34243e2669 href="https://www.pacer.gov/">https://www.pacer.gov/</a>. Filed March 2, 2012. Accessed/link verified July 31, 2015. (Page numbers, where listed, are based on the PageID of the file.) <a target=xrefwindow id=d34243e2672 href="https://ecf.njd.uscourts.gov/doc1/11916640939">Reference Source</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d34243e2681 class=n-a></a>Case 3:03-cv-01519-AET-TJB. Document 328-6. Available through the Public Access to Court Electronic Records (PACER) database: <a target=xrefwindow id=d34243e2683 href="https://www.pacer.gov/">https://www.pacer.gov/</a>. Filed March 2, 2012. Accessed/link verified July 31, 2015. (Page numbers, where listed, are based on the PageID of the file.) <a target=xrefwindow id=d34243e2686 href="https://ecf.njd.uscourts.gov/doc1/11916640942">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d34243e2695 class=n-a></a>Case 3:03-cv-01519-AET-TJB. Document 328-10. Available through the Public Access to Court Electronic Records (PACER) database: <a target=xrefwindow id=d34243e2697 href="https://www.pacer.gov/">https://www.pacer.gov/</a>. Filed March 2, 2012. Accessed/link verified July 31, 2015. (Page numbers, where listed, are based on the PageID of the file.) <a target=xrefwindow id=d34243e2700 href="https://ecf.njd.uscourts.gov/doc1/11916640946">Reference Source</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d34243e2709 class=n-a></a>Singh G, Fort JG, Goldstein JL, <i> et al.</i>: Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. <i>Am J Med.</i> 2006; <b>119</b>(3): 255–266. <a target=xrefwindow id=d34243e2720 href="http://www.ncbi.nlm.nih.gov/pubmed/16490472">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2723 href="http://dx.doi.org/10.1016/j.amjmed.2005.09.054">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d34243e2733 class=n-a></a>Chan FK, Lanas A, Scheiman J, <i> et al.</i>: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. <i>Lancet.</i> 2010; <b>376</b>(9736): 173–179. <a target=xrefwindow id=d34243e2744 href="http://www.ncbi.nlm.nih.gov/pubmed/20638563">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2747 href="http://dx.doi.org/10.1016/S0140-6736(10)60673-3">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d34243e2756 class=n-a></a>Cryer B, Li C, Simon LS, <i> et al.</i>: GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. <i>Am J Gastroenterol.</i> 2013; <b>108</b>(3): 392–400. <a target=xrefwindow id=d34243e2767 href="http://www.ncbi.nlm.nih.gov/pubmed/23399552">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2770 href="http://dx.doi.org/10.1038/ajg.2012.467">Publisher Full Text </a> | <a target=xrefwindow id=d34243e2774 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3590424">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d34243e2783 class=n-a></a>Committee on Finance, United States Senate: Committee Staff Report to the Chairman and Ranking Member. The Intimidation of Dr. John Buse and the Diabetes Drug Avandia. 2007. <a target=xrefwindow id=d34243e2785 href="http://www.finance.senate.gov/download/?id=883E903D-F973-4A74-8432-3C651C71B4B4">Reference Source</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d34243e2794 class=n-a></a>Committee on Finance, United States Senate: Baucus, Grassley find company failed to promptly alert FDA about drug risks. 2010. <a target=xrefwindow id=d34243e2796 href="http://www.finance.senate.gov/newsroom/chairman/release/?id=bcf5aef6-9bc5-45ca-9cab-aadf5df135fa">Reference Source</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d34243e2805 class=n-a></a>Committee on Finance, United States Senate: Finance Committee letter to the FDA regarding Avandia. 2010. (Page numbers, where listed, are based on consecutive physical page count in this letter due to pagination in the letter stopping after the official body of the letter.) <a target=xrefwindow id=d34243e2807 href="http://www.finance.senate.gov/newsroom/chairman/download/?id=a5c07780-6351-4905-8c63-52e4a7a7a66b">Reference Source</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d34243e2816 class=n-a></a>Committee on Finance, United States Senate with Max Baucus, Chairman and Chuck Grassley, Ranking Member: Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. 2010. <a target=xrefwindow id=d34243e2818 href="http://www.finance.senate.gov/newsroom/chairman/download/?id=9e4b091f-de21-4df1-b65e-b227d74bec12">Reference Source</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d34243e2828 class=n-a></a>Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. <i>N Engl J Med.</i> 2007; <b>356</b>(24): 2457–2471. <a target=xrefwindow id=d34243e2836 href="http://www.ncbi.nlm.nih.gov/pubmed/17517853">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2839 href="http://dx.doi.org/10.1056/NEJMoa072761">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d34243e2848 class=n-a></a>Home PD, Pocock SJ, Beck-Nielsen H, <i> et al.</i>: Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. <i>N Engl J Med.</i> 2007; <b>357</b>(1): 28–38. <a target=xrefwindow id=d34243e2859 href="http://www.ncbi.nlm.nih.gov/pubmed/17551159">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2862 href="http://dx.doi.org/10.1056/NEJMoa073394">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d34243e2871 class=n-a></a>Drazen JM, Morrissey S, Curfman GD: Rosiglitazone--continued uncertainty about safety. <i>N Engl J Med.</i> 2007; <b>357</b>(1): 63–64. <a target=xrefwindow id=d34243e2879 href="http://www.ncbi.nlm.nih.gov/pubmed/17551160">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2882 href="http://dx.doi.org/10.1056/NEJMe078118">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d34243e2891 class=n-a></a>Nathan DM: Rosiglitazone and cardiotoxicity--weighing the evidence. <i>N Engl J Med.</i> 2007; <b>357</b>(1): 64–66. <a target=xrefwindow id=d34243e2899 href="http://www.ncbi.nlm.nih.gov/pubmed/17551161">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2902 href="http://dx.doi.org/10.1056/NEJMe078117">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d34243e2911 class=n-a></a>Psaty BM, Furberg CD: The record on rosiglitazone and the risk of myocardial infarction. <i>N Engl J Med.</i> 2007; <b>357</b>(1): 67–69. <a target=xrefwindow id=d34243e2919 href="http://www.ncbi.nlm.nih.gov/pubmed/17551162">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2922 href="http://dx.doi.org/10.1056/NEJMe078116">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d34243e2931 class=n-a></a>Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. <i>Arch Intern Med.</i> 2010; <b>170</b>(14): 1191–1201. <a target=xrefwindow id=d34243e2939 href="http://www.ncbi.nlm.nih.gov/pubmed/20656674">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2942 href="http://dx.doi.org/10.1001/archinternmed.2010.207">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d34243e2952 class=n-a></a>Mahaffey KW, Hafley G, Dickerson S, <i> et al.</i>: Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>Am Heart J.</i> 2013; <b>166</b>(2): 240–249.e1. <a target=xrefwindow id=d34243e2963 href="http://www.ncbi.nlm.nih.gov/pubmed/23895806">PubMed Abstract </a> | <a target=xrefwindow id=d34243e2966 href="http://dx.doi.org/10.1016/j.ahj.2013.05.004">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d34243e2975 class=n-a></a>Department of Justice, Office of Public Affairs: GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. 2012. <a target=xrefwindow id=d34243e2977 href="http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report">Reference Source</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d34243e2986 class=n-a></a>The BMJ: Tamiflu timeline. Accessed/link verified December 23, 2014. <a target=xrefwindow id=d34243e2988 href="http://embed.verite.co/timeline/?source=0Aq8WxSy6z4gAdFV6anBySFppYWNZOUtBZHRDTUoxb1E&amp;font=Bevan-PotanoSans&amp;maptype=toner&amp;lang=en&amp;height=650">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d34243e2997 class=n-a></a>Jefferson TO, Demicheli V, Di Pietrantonj C, <i> et al.</i>: Neuraminidase inhibitors for preventing and treating influenza in healthy adults. <i>Cochrane Database Syst Rev.</i> 2006; (3): CD001265. <a target=xrefwindow id=d34243e3005 href="http://www.ncbi.nlm.nih.gov/pubmed/16855962">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3008 href="http://dx.doi.org/10.1002/14651858.CD001265.pub2">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d34243e3017 class=n-a></a>Kaiser L, Wat C, Mills T, <i> et al.</i>: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. <i>Arch Intern Med.</i> 2003; <b>163</b>(14): 1667–1672. <a target=xrefwindow id=d34243e3028 href="http://www.ncbi.nlm.nih.gov/pubmed/12885681">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3031 href="http://dx.doi.org/10.1001/archinte.163.14.1667">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d34243e3040 class=n-a></a>The BMJ: Open Data campaign. Accessed/link verified December 20, 2014. <a target=xrefwindow id=d34243e3042 href="http://www.bmj.com/open-data">Reference Source</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d34243e3052 class=n-a></a>The BMJ: Tamiflu campaign. Accessed/link verified December 20, 2014. <a target=xrefwindow id=d34243e3054 href="http://www.bmj.com/tamiflu">Reference Source</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d34243e3063 class=n-a></a>Doshi P: Neuraminidase inhibitors--the story behind the Cochrane review. <i>BMJ.</i> 2009; <b>339</b>: b5164. <a target=xrefwindow id=d34243e3071 href="http://www.ncbi.nlm.nih.gov/pubmed/19995813">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3074 href="http://dx.doi.org/10.1136/bmj.b5164">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d34243e3083 class=n-a></a>Jefferson T, Jones M, Doshi P, <i> et al.</i>: Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. <i>BMJ.</i> 2009; <b>339</b>: b5106. <a target=xrefwindow id=d34243e3094 href="http://www.ncbi.nlm.nih.gov/pubmed/19995812">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3097 href="http://dx.doi.org/10.1136/bmj.b5106">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3101 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2790574">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d34243e3110 class=n-a></a>Jefferson T, Jones M, Doshi P, <i> et al.</i>: Neuraminidase inhibitors for preventing and treating influenza in healthy adults. <i>Cochrane Database Syst Rev.</i> 2010; (2): CD001265. <a target=xrefwindow id=d34243e3118 href="http://www.ncbi.nlm.nih.gov/pubmed/20166059">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3121 href="http://dx.doi.org/10.1002/14651858.CD001265.pub3">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d34243e3130 class=n-a></a>Godlee F, Clarke M: Why don’t we have all the evidence on oseltamivir? <i>BMJ.</i> 2009; <b>339</b>: b5351. <a target=xrefwindow id=d34243e3138 href="http://www.ncbi.nlm.nih.gov/pubmed/19995815">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3141 href="http://dx.doi.org/10.1136/bmj.b5351">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d34243e3150 class=n-a></a>Godlee F: We want raw data, now. <i>BMJ.</i> 2009; <b>339</b>: b5405. <a target=xrefwindow id=d34243e3158 href="http://dx.doi.org/10.1136/bmj.b5405">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d34243e3168 class=n-a></a>Cohen D: Complications: tracking down the data on oseltamivir. <i>BMJ.</i> 2009; <b>339</b>: b5387. <a target=xrefwindow id=d34243e3176 href="http://www.ncbi.nlm.nih.gov/pubmed/19995818">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3179 href="http://dx.doi.org/10.1136/bmj.b5387">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d34243e3188 class=n-a></a>Jefferson T, Doshi P, Thompson M, <i> et al.</i>: Ensuring safe and effective drugs: who can do what it takes? <i>BMJ.</i> 2011; <b>342</b>: c7258. <a target=xrefwindow id=d34243e3199 href="http://www.ncbi.nlm.nih.gov/pubmed/21224325">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3202 href="http://dx.doi.org/10.1136/bmj.c7258">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d34243e3211 class=n-a></a>Payne D: Tamiflu: the battle for secret drug data. <i>BMJ.</i> 2012; <b>345</b>: e7303. <a target=xrefwindow id=d34243e3219 href="http://www.ncbi.nlm.nih.gov/pubmed/23109482">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3222 href="http://dx.doi.org/10.1136/bmj.e7303">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d34243e3231 class=n-a></a>Doshi P, Jefferson T, Del Mar C: The imperative to share clinical study reports: recommendations from the Tamiflu experience. <i>PLoS Med.</i> 2012; <b>9</b>(4): e1001201. <a target=xrefwindow id=d34243e3239 href="http://www.ncbi.nlm.nih.gov/pubmed/22505850">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3242 href="http://dx.doi.org/10.1371/journal.pmed.1001201">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3245 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3323511">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d34243e3254 class=n-a></a>Jefferson T, Jones MA, Doshi P, <i> et al.</i>: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. <i>Cochrane Database Syst Rev.</i> 2012; <b>1</b>: CD008965. <a target=xrefwindow id=d34243e3265 href="http://www.ncbi.nlm.nih.gov/pubmed/22258996">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3268 href="http://dx.doi.org/10.1002/14651858.CD008965.pub3">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d34243e3277 class=n-a></a>Jefferson T, Jones MA, Doshi P, <i> et al.</i>: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. <i>Cochrane Database Syst Rev.</i> 2014; <b>4</b>: CD008965. <a target=xrefwindow id=d34243e3288 href="http://www.ncbi.nlm.nih.gov/pubmed/24718923">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3291 href="http://dx.doi.org/10.1002/14651858.CD008965.pub4">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d34243e3301 class=n-a></a>Loder E, Tovey D, Godlee F: The Tamiflu trials. <i>BMJ.</i> 2014; <b>348</b>: g2630. <a target=xrefwindow id=d34243e3309 href="http://www.ncbi.nlm.nih.gov/pubmed/24811414">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3312 href="http://dx.doi.org/10.1136/bmj.g2630">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d34243e3321 class=n-a></a>Jefferson T, Jones MA, Doshi P, <i> et al.</i>: Data from: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. <i>Dryad Digital Repository.</i> 2014. <a target=xrefwindow id=d34243e3329 href="http://dx.doi.org/10.5061/dryad.77471">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d34243e3338 class=n-a></a>Jefferson T, Jones M, Doshi P, <i> et al.</i>: Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. <i>BMJ.</i> 2014; <b>348</b>: g2545. <a target=xrefwindow id=d34243e3349 href="http://www.ncbi.nlm.nih.gov/pubmed/24811411">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3352 href="http://dx.doi.org/10.1136/bmj.g2545">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3356 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3981975">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d34243e3365 class=n-a></a>Dobson J, Whitley RJ, Pocock S, <i> et al.</i>: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet.</i> 2015; <b>385</b>(9979): 1729–1737. <a target=xrefwindow id=d34243e3376 href="http://www.ncbi.nlm.nih.gov/pubmed/25640810">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3379 href="http://dx.doi.org/10.1016/S0140-6736(14)62449-1">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d34243e3388 class=n-a></a>Wenzel RP, Fowler AA 3rd: Clinical practice. Acute bronchitis. <i>N Engl J Med.</i> 2006; <b>355</b>(20): 2125–2130. <a target=xrefwindow id=d34243e3396 href="http://www.ncbi.nlm.nih.gov/pubmed/17108344">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3399 href="http://dx.doi.org/10.1056/NEJMcp061493">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d34243e3408 class=n-a></a>Ward JI, Cherry JD, Chang SJ, <i> et al.</i>: Efficacy of an acellular pertussis vaccine among adolescents and adults. <i>N Engl J Med.</i> 2005; <b>353</b>(15): 1555–1563. <a target=xrefwindow id=d34243e3419 href="http://www.ncbi.nlm.nih.gov/pubmed/16221778">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3422 href="http://dx.doi.org/10.1056/NEJMoa050824">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d34243e3432 class=n-a></a>Centers for Disease Control and Prevention: Get smart: Know when antibiotics work – Bronchitis (chest cold). Last updated April 17, 2015. Accessed/link verified July 25, 2015. <a target=xrefwindow id=d34243e3434 href="http://www.cdc.gov/getsmart/community/for-patients/common-illnesses/bronchitis.html">Reference Source</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d34243e3443 class=n-a></a>De Angelis C, Drazen JM, Frizelle FA, <i> et al.</i>: Clinical trial registration: a statement from the International Committee of Medical Journal Editors. <i>N Engl J Med.</i> 2004; <b>351</b>(12): 1250–1251. <a target=xrefwindow id=d34243e3454 href="http://www.ncbi.nlm.nih.gov/pubmed/15356289">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3457 href="http://dx.doi.org/10.1056/NEJMe048225">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d34243e3466 class=n-a></a>U.S. National Institutes of Health: ClinicalTrials.gov background. Accessed/link verified August 25, 2014. <a target=xrefwindow id=d34243e3468 href="https://clinicaltrials.gov/ct2/about-site/background">Reference Source</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d34243e3477 class=n-a></a>De Angelis CD, Drazen JM, Frizelle FA, <i> et al.</i>: Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors. <i>N Engl J Med.</i> 2005; <b>352</b>(23): 2436–2438. <a target=xrefwindow id=d34243e3488 href="http://www.ncbi.nlm.nih.gov/pubmed/15911780">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3491 href="http://dx.doi.org/10.1056/NEJMe058127">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d34243e3500 class=n-a></a>Mathieu S, Boutron I, Moher D, <i> et al.</i>: Comparison of registered and published primary outcomes in randomized controlled trials. <i>JAMA.</i> 2009; <b>302</b>(9): 977–84. <a target=xrefwindow id=d34243e3511 href="http://www.ncbi.nlm.nih.gov/pubmed/19724045">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3514 href="http://dx.doi.org/10.1001/jama.2009.1242">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d34243e3523 class=n-a></a>Jones CW, Platts-Mills TF: Quality of registration for clinical trials published in emergency medicine journals. <i>Ann Emerg Med.</i> 2012; <b>60</b>(4): 458–464.e1. <a target=xrefwindow id=d34243e3531 href="http://www.ncbi.nlm.nih.gov/pubmed/22503374">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3534 href="http://dx.doi.org/10.1016/j.annemergmed.2012.02.005">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d34243e3544 class=n-a></a>Killeen S, Sourallous P, Hunter IA, <i> et al.</i>: Registration rates, adequacy of registration, and a comparison of registered and published primary outcomes in randomized controlled trials published in surgery journals. <i>Ann Surg.</i> 2014; <b>259</b>(1): 193–196. <a target=xrefwindow id=d34243e3555 href="http://www.ncbi.nlm.nih.gov/pubmed/23732270">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3558 href="http://dx.doi.org/10.1097/SLA.0b013e318299d00b">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d34243e3567 class=n-a></a>The Food and Drug Administration: FDA Amendments Act of 2007. 2007. [In particular, see pages 82 (<a target=xrefwindow id=d34243e3569 href="http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82">http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=82</a>), 91 (<a target=xrefwindow id=d34243e3572 href="http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=91">http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=91</a>), and 98 (<a target=xrefwindow id=d34243e3575 href="http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=98">http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf#page=98</a>), with the areas referenced therein and pages between also being recommended.] <a target=xrefwindow id=d34243e3578 href="http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d34243e3587 class=n-a></a>U.S. National Institutes of Health: FDAAA 801 Requirements. <i>ClinicalTrials.gov.</i> Last reviewed December 2014. Accessed/link verified December 19, 2014. <a target=xrefwindow id=d34243e3592 href="https://www.clinicaltrials.gov/ct2/manage-recs/fdaaa">Reference Source</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d34243e3601 class=n-a></a>Prayle AP, Hurley MN, Smyth AR: Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. <i>BMJ.</i> 2012; <b>344</b>: d7373. <a target=xrefwindow id=d34243e3609 href="http://www.ncbi.nlm.nih.gov/pubmed/22214756">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3612 href="http://dx.doi.org/10.1136/bmj.d7373">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d34243e3621 class=n-a></a>Huser V, Cimino JJ: Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. <i>PLoS One.</i> 2013; <b>8</b>(7): e68409. <a target=xrefwindow id=d34243e3629 href="http://www.ncbi.nlm.nih.gov/pubmed/23874614">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3632 href="http://dx.doi.org/10.1371/journal.pone.0068409">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3635 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3706420">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d34243e3644 class=n-a></a>Jones CW, Handler L, Crowell KE, <i> et al.</i>: Non-publication of large randomized clinical trials: cross sectional analysis. <i>BMJ.</i> 2013; <b>347</b>: f6104. <a target=xrefwindow id=d34243e3655 href="http://www.ncbi.nlm.nih.gov/pubmed/24169943">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3658 href="http://dx.doi.org/10.1136/bmj.f6104">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3662 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3812466">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d34243e3672 class=n-a></a>Law MR, Kawasumi Y, Morgan SG: Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. <i>Health Aff (Millwood).</i> 2011; <b>30</b>(12): 2338–45. <a target=xrefwindow id=d34243e3680 href="http://www.ncbi.nlm.nih.gov/pubmed/22147862">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3683 href="http://dx.doi.org/10.1377/hlthaff.2011.0172">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d34243e3692 class=n-a></a>Kirillova O: Results and outcome reporting in ClinicalTrials.gov, what makes it happen? <i>PLoS One.</i> 2012; <b>7</b>(6): e37847. <a target=xrefwindow id=d34243e3700 href="http://www.ncbi.nlm.nih.gov/pubmed/22719853">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3703 href="http://dx.doi.org/10.1371/journal.pone.0037847">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3706 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3374834">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d34243e3715 class=n-a></a>Giel JL: Comparison of results reporting on ClinicalTrials.gov by funding source. <i>Curr Med Res Opin.</i> 2011; <b>27</b>(Suppl 1): S8. (only available in an abstract format due to it being from a presentation at the Annual Meeting of the International Society for Medical Publication Professionals). <a target=xrefwindow id=d34243e3723 href="http://dx.doi.org/10.1185/03007995.2011.564047">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d34243e3732 class=n-a></a>Ross JS, Mulvey GK, Hines EM, <i> et al.</i>: Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. <i>PLoS Med.</i> 2009; <b>6</b>(9): e1000144. <a target=xrefwindow id=d34243e3743 href="http://www.ncbi.nlm.nih.gov/pubmed/19901971">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3746 href="http://dx.doi.org/10.1371/journal.pmed.1000144">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3750 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2728480">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d34243e3759 class=n-a></a>Anderson ML, Chiswell K, Peterson ED, <i> et al.</i>: Compliance with results reporting at ClinicalTrials.gov. <i>N Engl J Med.</i> 2015; <b>372</b>(11): 1031–1039. <a target=xrefwindow id=d34243e3770 href="http://www.ncbi.nlm.nih.gov/pubmed/25760355">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3773 href="http://dx.doi.org/10.1056/NEJMsa1409364">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4508873">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d34243e3786 class=n-a></a>Mathieu S, Chan AW, Ravaud P: Use of trial register information during the peer review process. <i>PLoS One.</i> 2013; <b>8</b>(4): e59910. <a target=xrefwindow id=d34243e3794 href="http://www.ncbi.nlm.nih.gov/pubmed/23593154">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3797 href="http://dx.doi.org/10.1371/journal.pone.0059910">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3800 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3622662">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d34243e3810 class=n-a></a>National Institutes of Health, Department of Health and Human Services: 42 CFR part 11 [docket number NIH–2011–0003], RIN 0925–AA52, clinical trials registration and results submission, action: notice of proposed rulemaking. <i>Federal Register.</i> 2014; <b>79</b>(225). <a target=xrefwindow id=d34243e3818 href="http://www.gpo.gov/fdsys/pkg/FR-2014-11-21/pdf/2014-26197.pdf">Reference Source</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d34243e3827 class=n-a></a>U.S. National Institutes of Health: HHS and NIH take steps to enhance transparency of clinical trial results. 2014. <a target=xrefwindow id=d34243e3829 href="http://www.nih.gov/news/health/nov2014/od-19.htm">Reference Source</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d34243e3838 class=n-a></a>U.S. National Institutes of Health: Summary of HHS/NIH proposals to enhance transparency of clinical trial results. 2014. <a target=xrefwindow id=d34243e3840 href="http://www.nih.gov/news/health/nov2014/od-19_summary.htm">Reference Source</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d34243e3849 class=n-a></a>AllTrials Initiative: About AllTrials. Accessed/link verified December 3, 2014. <a target=xrefwindow id=d34243e3851 href="http://www.alltrials.net/find-out-more/about-alltrials/">Reference Source</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d34243e3860 class=n-a></a>AllTrials Initiative: What does all trials registered and reported mean? Accessed/link verified December 3, 2014. <a target=xrefwindow id=d34243e3862 href="http://www.alltrials.net/find-out-more/all-trials/">Reference Source</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d34243e3871 class=n-a></a>AllTrials Initiative: Supporters. Accessed/link verified June 21, 2015. <a target=xrefwindow id=d34243e3873 href="http://www.alltrials.net/supporters/">Reference Source</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d34243e3883 class=n-a></a>Godlee F: One promise fulfilled, much still to be done. <i>BMJ.</i> 2015; <b>350</b>: g7811. <a target=xrefwindow id=d34243e3891 href="http://dx.doi.org/10.1136/bmj.g7811">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d34243e3900 class=n-a></a>Doshi P, Dickersin K, Healy D, <i> et al.</i>: Restoring invisible and abandoned trials: a call for people to publish the findings. <i>BMJ.</i> 2013; <b>346</b>: f2865. <a target=xrefwindow id=d34243e3911 href="http://www.ncbi.nlm.nih.gov/pubmed/23766480">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3914 href="http://dx.doi.org/10.1136/bmj.f2865">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3685516">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d34243e3927 class=n-a></a>Treasure T, Monson K, Fiorentino F, <i> et al.</i>: The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. <i>BMJ Open.</i> 2014; <b>4</b>(5): e004385. <a target=xrefwindow id=d34243e3938 href="http://www.ncbi.nlm.nih.gov/pubmed/24823671">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3941 href="http://dx.doi.org/10.1136/bmjopen-2013-004385">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4025449">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d34243e3954 class=n-a></a>Lo B, Coetzee T, Demets D, <i> et al.</i>: Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy, Institute of Medicine. Sharing clinical trial data: Maximizing benefits, minimizing risk. ISBN 978-0-309-31629-3, National Academies Press, 2015. <a target=xrefwindow id=d34243e3959 href="http://www.nap.edu/catalog/18998/sharing-clinical-trial-data-maximizing-benefits-minimizing-risk">Reference Source</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d34243e3968 class=n-a></a>Moorthy VS, Karam G, Vannice KS, <i> et al.</i>: Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results. <i>PLoS Med.</i> 2015; <b>12</b>(4): e1001819. <a target=xrefwindow id=d34243e3979 href="http://www.ncbi.nlm.nih.gov/pubmed/25874642">PubMed Abstract </a> | <a target=xrefwindow id=d34243e3982 href="http://dx.doi.org/10.1371/journal.pmed.1001819">Publisher Full Text </a> | <a target=xrefwindow id=d34243e3986 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4396122">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d34243e3995 class=n-a></a>World Medical Association: WMA Declaration of Helsinki: ethical principles for medical research involving human subjects.2013 October. Accessed/link verified August 7, 2015. <a target=xrefwindow id=d34243e3997 href="http://www.wma.net/en/30publications/10policies/b3/">Reference Source</a></span></li></ul></div></div></div> </div> <div class=f1r-article-desk> <section class="o-box o-box--medium u-bg--2 u-mt--2"> <h4 class="u-mt--0 u-mb--2 t-h3 u-weight--md">Looking for the Open Peer Review Reports?</h4> <p class="u-mt--0 u-mb--0 t-h4">They can now be found at the top of the panel on the right, linked from the box entitled Open Peer Review. Choose the reviewer report you wish to read and click the 'read' link. You can also read all the peer review reports by <a target=_blank href="https://f1000research.com/articles/4-609/v2/pdf?article_uuid=f17622e0-1667-4ef9-bcca-d9d7a18fc66b">downloading the PDF</a>.</p> </section> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 2 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 2</span> <span class=details>PUBLISHED 21 Aug 2015</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/4-609/v2&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/4-609/v2&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Physician Assistant Studies, College of Allied Health Sciences, East Carolina University, Greenville, NC, 27858-4353, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (2)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/4-609/v2" title="Open version 2 of this article." class="" gahelper=2>version 2</a> <span class="article-pubinfo-mobile versions-section"> <div title="#springMessage("NewVersionReasonType.REVISED.tooltip")" class="version-info-box revised ">Revised</div> </span> </div> <div> Published: 05 Nov 2015, 4:609 </div> <div class=margin-bottom><a href="https://doi.org/10.12688/f1000research.6878.2">https://doi.org/10.12688/f1000research.6878.2</a></div> <div> <a href="https://f1000research.com/articles/4-609/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 21 Aug 2015, 4:609 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.6878.1">https://doi.org/10.12688/f1000research.6878.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2015 Mayer M. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=7887 data-id=6878 data-downloads="" data-views="" data-scholar="10.12688/f1000research.6878.2" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/4-609/v2/pdf?article_uuid=f17622e0-1667-4ef9-bcca-d9d7a18fc66b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.6878.2"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Mayer M. Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract [version 2; peer review: awaiting peer review] <i>F1000Research</i> 2015, <b>4</b>:609 (<a href="https://doi.org/10.12688/f1000research.6878.2" target=_blank>https://doi.org/10.12688/f1000research.6878.2</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=6878 id=mobile-track-article-signin-6878 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/6878?target=/articles/4-609/v2"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=7887 /> <input name=articleId type=hidden value=6878 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status no-border-and-margin "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <div class=f1r-article-desk-inline><em>AWAITING PEER REVIEW</em></div> <div class="f1r-article-mobile-inline float-right"><em>AWAITING PEER REVIEW</em></div> <span class="circle-icon-small to-right" data-window=about-referee-status title=Help>?</span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 2 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 2</span> <span class=details>PUBLISHED 21 Aug 2015</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/4-609/v2&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/4-609/v2&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <div class="p-article__sidebar-highlight u-mb--2"> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="u-ib u-middle"><em>AWAITING PEER REVIEW</em></div> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/4-609/v2&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/4-609/v2/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Peering into the \u201Crabbit hole\u201D...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/4-609/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/4-609/v2&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/4-609/v2" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Mayer M');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/4-609/v2/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/4-609",
            templates : {
                twitter : "Peering into the \u201Crabbit hole\u201D of publication bias.... Mayer M, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/4-609/v2"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Peering into the \u201Crabbit hole\u201D of publication bias and inadequate research transparency: Adding tangibility to the abstract", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Opinion Article", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Peering into the \u201Crabbit hole\u201D of publication bias and inadequate research transparency: Adding tangibility to the abstract", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/6878/7887")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("articles", "article", "7887");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "10048": 0,
                           "10049": 0,
                           "10050": 0,
                           "10051": 0,
                           "10631": 0,
                           "10632": 0,
                           "10636": 0,
                           "10637": 0,
                           "10638": 0,
                           "10639": 0,
                           "11824": 0,
                           "11825": 0,
                           "11826": 0,
                           "11827": 0,
                           "11828": 0,
                           "11829": 0,
                           "11830": 0,
                           "11127": 0,
                           "10045": 0,
                           "10046": 0,
                           "10047": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d3e62a54-c115-4ebf-90b9-423f75a2d396";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/4-609.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/4-609.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/4-609.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/4-609.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/4-609.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>